Third _RARE_
, O
consistent O
with O
these O
data O
, O
N I-GENE
- I-GENE
acetylcysteine _RARE_
reduced O
the O
stimulatory _RARE_
effect O
of O
HGF I-GENE
on O
stress I-GENE
kinase I-GENE
activities O
, O
while O
p42 _RARE_
/ I-GENE
44 O
mitogen I-GENE
activated I-GENE
kinase I-GENE
( O
MAPK I-GENE
) O
was O
unmodified _RARE_
, O
suggesting O
an O
involvement O
of O
c I-GENE
- I-GENE
Jun I-GENE
- I-GENE
N I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
( O
JNK I-GENE
) O
and O
p38 I-GENE
MAPK I-GENE
in O
HIF I-GENE
- I-GENE
1 I-GENE
activation O
. O

The O
Sox _RARE_
gene I-GENE
family I-GENE
( O
Sry _RARE_
like I-GENE
HMG I-GENE
box I-GENE
gene I-GENE
) O
is O
characterised _RARE_
by O
a O
conserved O
DNA I-GENE
sequence I-GENE
encoding O
a O
domain I-GENE
of O
approximately O
80 O
amino O
acids O
which O
is O
responsible O
for O
sequence I-GENE
specific I-GENE
DNA I-GENE
binding I-GENE
. O

Respiratory _RARE_
parameters O
suggested O
that O
M6G _RARE_
produced O
less O
respiratory O
depression O
than O
morphine O
. O

This O
slow O
progression O
through O
the O
early I-GENE
G1 I-GENE
- I-GENE
phase O
resulted O
in O
decreased O
phosphorylation O
of O
the O
RB I-GENE
protein I-GENE
and O
subsequent O
delay O
into O
the O
S I-GENE
phase O
transition O
. O

Responses _RARE_
of O
TLD _RARE_
Mg2SiO4 _RARE_
: O
Tb _RARE_
and O
radiophotoluminescent _RARE_
glass O
to O
heavy I-GENE
charged O
particles O
and O
space O
radiation O
. O

In O
the O
meantime _RARE_
, O
one O
has O
succeeded _RARE_
to O
establish O
the O
deammonification _RARE_
processes O
in O
a O
continuous O
flow O
moving _RARE_
- I-GENE
bed _RARE_
pilot _RARE_
plant O
. O

An O
18 O
- I-GENE
kb O
genomic O
clone O
including O
sequences I-GENE
encoding O
for O
the O
two O
GHS _RARE_
- I-GENE
R I-GENE
variants I-GENE
was O
isolated O
. O

In O
the O
further O
development O
of O
bladder O
neck O
suspension _RARE_
according O
to O
Stamey _RARE_
- I-GENE
Pereyra _RARE_
, O
the O
use O
of O
miniature _RARE_
bone O
anchors _RARE_
received O
considerable O
support O
. O

CHAP _RARE_
and O
the O
Department _RARE_
of O
Veterans _RARE_
Affairs _RARE_
. O

Finally O
, O
a O
chromogenic _RARE_
method O
was O
used O
, O
based O
on O
thrombin I-GENE
inhibition O
and O
the O
substrate I-GENE
S I-GENE
- I-GENE
2238 _RARE_
. O

As O
an O
oral O
, O
nontoxic _RARE_
compound O
with O
a O
mechanism O
of O
action O
distinct O
from O
that O
of O
ABL I-GENE
tyrosine I-GENE
kinase I-GENE
inhibition O
, O
FTI _RARE_
SCH66336 _RARE_
shows O
promise _RARE_
for O
the O
treatment O
of O
BCR I-GENE
/ I-GENE
ABL I-GENE
- I-GENE
induced O
leukemia I-GENE
. O

Recruitment _RARE_
of O
an O
RNA I-GENE
polymerase I-GENE
II I-GENE
complex I-GENE
is O
mediated O
by O
the O
constitutive O
activation O
domain I-GENE
in O
CREB I-GENE
, O
independently O
of O
CREB I-GENE
phosphorylation O
. O

Our O
results O
are O
reassuring _RARE_
and O
we O
therefore O
advise _RARE_
that O
in O
patients O
undergoing O
free O
jejunum _RARE_
flap O
reconstruction O
of O
the O
hypopharyngo _RARE_
- I-GENE
esophageal O
tract O
voice _RARE_
restoration _RARE_
should O
be O
attempted _RARE_
by O
placing _RARE_
a O
voice _RARE_
prosthesis _RARE_
through O
a O
secondary O
tracheo _RARE_
- I-GENE
esophageal O
puncture _RARE_
and O
providing O
intensive O
speech O
training O
. O

Regarding _RARE_
gestational O
risk O
, O
3 I-GENE
, O
243 _RARE_
drugs O
used O
( O
34 O
%) O
belonged _RARE_
to O
category O
A I-GENE
risk O
, O
1 I-GENE
, O
923 _RARE_
( O
22 O
. O
6 I-GENE
%) O
to O
category O
B I-GENE
, O
3 I-GENE
, O
798 _RARE_
( O
39 O
. O
7 O
%) O
to O
category O
C I-GENE
, O
289 _RARE_
( O
3 I-GENE
. O
0 O
%) O
to O
category O
D I-GENE
, O
and O
55 O
( O
0 O
. O
6 I-GENE
%) O
to O
category O
X I-GENE
. O

The O
human I-GENE
ABCG1 _RARE_
gene I-GENE
encodes O
a O
member O
of O
the O
ATP I-GENE
- I-GENE
binding I-GENE
cassette _RARE_
( O
ABC _RARE_
) O
superfamily I-GENE
of O
transporter I-GENE
proteins I-GENE
and O
is O
highly O
induced O
when O
macrophages O
are O
incubated O
with O
oxysterols _RARE_
. O

At O
the O
end O
of O
each O
day O
of O
migration O
the O
pulmonary O
hemolymph _RARE_
PO2 O
decreased O
by O
1 I-GENE
- I-GENE
2 I-GENE
. O
5 I-GENE
kPa _RARE_
, O
but O
the O
hemocyanin _RARE_
remained O
saturated _RARE_
with O
O2 O
and O
the O
venous O
reserve O
was O
largely O
unchanged O
( O
O2 O
> O
0 O
. O
4 I-GENE
mmol O
x O
l O
(- O
1 I-GENE
)). _RARE_

We O
have O
investigated O
the O
role O
of O
NGF _RARE_
in O
regulating O
gene I-GENE
transcription I-GENE
in O
PC12 O
and O
INS _RARE_
- I-GENE
1 I-GENE
cells O
, O
in O
order O
to O
define O
if O
there O
are O
NGF _RARE_
- I-GENE
regulated O
genes I-GENE
per O
se _RARE_
. O

Thus O
, O
through O
a O
change O
in O
conformation O
upon O
repair I-GENE
of O
the O
6RG _RARE_
lesion O
, O
MGMT _RARE_
switches _RARE_
from O
a O
DNA I-GENE
repair I-GENE
factor I-GENE
to O
a O
transcription I-GENE
regulator I-GENE
( O
R I-GENE
- I-GENE
MGMT _RARE_
), O
enabling _RARE_
the O
cell O
to O
sense O
as O
well O
as O
respond O
to O
mutagens _RARE_
. O

TaqMan _RARE_
analysis O
of O
gene I-GENE
expression O
following O
chronic O
FA _RARE_
treatment O
showed O
neither O
a O
decrease O
in O
the O
amount O
of O
leptin I-GENE
receptor I-GENE
( O
Ob _RARE_
- I-GENE
R I-GENE
) O
mRNA I-GENE
, O
nor O
an O
increase O
in O
the O
negative O
regulators O
of O
STAT I-GENE
signalling O
, O
SOCS3 _RARE_
( O
suppressors O
of O
cytokine O
signalling O
) O
or O
cytokine O
inducible I-GENE
sequence I-GENE
( O
CIS _RARE_
). O

Nine _RARE_
animals O
served _RARE_
as O
control O
animals O
, O
whereas O
20 O
animals O
received O
a O
focal _RARE_
arachnoid _RARE_
scar _RARE_
at O
C1 I-GENE
- I-GENE
C2 I-GENE
, O
which O
was O
produced O
by O
placement O
of O
a O
kaolin _RARE_
- I-GENE
soaked _RARE_
fibrin I-GENE
sponge _RARE_
on O
the O
posterior O
surface I-GENE
of O
the O
spinal O
cord O
. O

A I-GENE
comparison O
of O
the O
duplicated O
Vkappa _RARE_
genes I-GENE
suggests O
positive O
selection O
on O
the O
complementarity _RARE_
- I-GENE
determining O
regions O
of O
the O
duplicated O
genes I-GENE
by O
point O
mutations O
. O

They O
have O
not O
been O
previously O
reported O
as O
a O
reaction O
to O
i O
. O
v I-GENE
. O
contrast O
material O
. O

The O
presence O
of O
AS _RARE_
- I-GENE
oligo _RARE_
had O
no O
further O
effect O
on O
the O
FSH I-GENE
- I-GENE
mediated O
activation O
of O
the O
EB _RARE_
*- _RARE_
mTf _RARE_
- I-GENE
CAT I-GENE
construct I-GENE
but O
reduced O
cAMP I-GENE
- I-GENE
mediated O
activation O
. O

The O
homologous I-GENE
active O
- I-GENE
site I-GENE
framework _RARE_
of O
these O
enzymes O
with O
distinct O
structures O
suggests O
convergent _RARE_
evolution O
of O
a O
common O
catalytic I-GENE
mechanism O
. O

Additional _RARE_
education O
and O
research O
is O
needed O
to O
provide O
further O
direction O
for O
intervention O
and O
incorporation O
into O
practice O
. O

Many O
of O
the O
important O
genes I-GENE
associated I-GENE
with O
G1 I-GENE
regulation O
have O
been O
shown O
to O
play O
a O
key O
role O
in O
proliferation O
, O
differentiation O
and O
oncogenic _RARE_
transformation O
and O
programmed O
cell O
death O
( O
apoptosis O
). O

Drug O
interactions O
have O
been O
found O
with O
drugs O
that O
compete O
for O
the O
same O
CYP450 _RARE_
isoenzymes _RARE_
as O
statins _RARE_
. O

Regulation O
of O
laminin _RARE_
beta2 _RARE_
chain I-GENE
gene I-GENE
expression O
in O
human I-GENE
cancer O
cell O
lines O
. O

Mutation O
of O
the O
NF I-GENE
- I-GENE
kappaB I-GENE
site I-GENE
in O
the O
Mdr1b _RARE_
promoter I-GENE
prevents O
its O
induction O
by O
TNF I-GENE
- I-GENE
alpha I-GENE
. O

Effect O
of O
heat I-GENE
treatments O
on O
the O
meltability _RARE_
of O
cheeses _RARE_
. O

In O
vitro O
binding I-GENE
studies O
demonstrate O
that O
eIF I-GENE
- I-GENE
5A _RARE_
is O
required O
for O
efficient O
interaction O
of O
Rev I-GENE
- I-GENE
NES _RARE_
with O
CRM1 _RARE_
/ I-GENE
exportin1 _RARE_
and O
that O
eIF I-GENE
- I-GENE
5A _RARE_
interacts O
with O
the O
nucleoporins _RARE_
CAN _RARE_
/ I-GENE
nup214 _RARE_
, O
nup153 _RARE_
, O
nup98 _RARE_
, O
and O
nup62 _RARE_
. O

Forced _RARE_
expression O
of O
BZAP45 _RARE_
strongly O
stimulates O
H4 I-GENE
promoter I-GENE
( O
nt O
- I-GENE
215 O
to O
- I-GENE
1 I-GENE
)/ O
CAT I-GENE
reporter I-GENE
gene I-GENE
activity O
. O

Copyright O
2001 _RARE_
Academic O
Press O
. O

The O
diagnosis O
of O
HCV I-GENE
arthritis O
in O
patients O
with O
positive O
rheumatoid I-GENE
factor I-GENE
and O
chronic O
inflammatory O
polyarthritis _RARE_
may O
be O
difficult O
. O

The O
UBA _RARE_
domains I-GENE
of O
RAD23 _RARE_
and O
DDI1 _RARE_
are O
required O
for O
these O
interactions O
. O

E47 _RARE_
protein I-GENE
levels O
remain _RARE_
high O
until O
the O
double I-GENE
positive O
developmental O
stage O
, O
at O
which O
point O
they O
drop O
to O
relatively O
moderate O
levels O
, O
and O
are O
further O
downregulated _RARE_
upon O
transition O
to O
the O
single O
positive O
stage O
. O

By O
Caveman _RARE_
. O

These O
findings O
suggest O
that O
the O
adapter _RARE_
Gab1 _RARE_
may O
redirect _RARE_
c I-GENE
- I-GENE
Met I-GENE
signaling O
through O
PI3K _RARE_
away _RARE_
from O
a O
c I-GENE
- I-GENE
Akt I-GENE
/ I-GENE
Pak1 _RARE_
cell O
survival O
pathway O
. O

Another O
mutant I-GENE
, O
T255A _RARE_
, O
lost O
the O
ability O
to O
bind O
E4orf6 _RARE_
, O
but O
unexpectedly _RARE_
, O
viral I-GENE
late O
- I-GENE
gene I-GENE
expression O
was O
not O
affected O
. O

However O
, O
the O
N63S _RARE_
mutation I-GENE
in O
the O
wild I-GENE
- I-GENE
type I-GENE
VP5 _RARE_
background O
increased O
the O
interaction O
, O
as O
judged O
by O
the O
beta I-GENE
- I-GENE
galactosidase I-GENE
activity O
, O
by O
a O
factor I-GENE
of O
9 O
relative O
to O
when O
the O
PR7 _RARE_
mutation I-GENE
was O
present O
. O

Here O
we O
report O
the O
isolation O
and O
characterization O
of O
the O
forkhead _RARE_
homologue I-GENE
in O
rhabdomyosarcoma _RARE_
( O
FKHR _RARE_
), O
a O
recently O
described O
member O
of O
the O
hepatocyte I-GENE
nuclear I-GENE
factor I-GENE
3 I-GENE
/ I-GENE
forkhead _RARE_
homeotic I-GENE
gene I-GENE
family I-GENE
, O
as O
a O
nuclear I-GENE
hormone I-GENE
receptor I-GENE
( O
NR _RARE_
) O
intermediary _RARE_
protein I-GENE
. O

Unlike O
other O
progenitor _RARE_
cells O
of O
the O
brain O
, O
SVZa _RARE_
progenitor _RARE_
cells O
have O
the O
capacity O
to O
divide _RARE_
even O
though O
they O
express O
a O
neuronal O
phenotype O
. O

We O
previously O
reported O
that O
Tax I-GENE
induced O
cell O
cycle O
progression O
from O
G0 _RARE_
/ I-GENE
G1 I-GENE
phase O
to O
S I-GENE
and O
G2 _RARE_
/ I-GENE
M I-GENE
phases O
in O
human I-GENE
T I-GENE
- I-GENE
cell O
line O
Kit _RARE_
225 _RARE_
cells O
. O

Phosphotyrosyl _RARE_
peptides I-GENE
block O
Stat3 I-GENE
- I-GENE
mediated O
DNA I-GENE
binding I-GENE
activity O
, O
gene I-GENE
regulation O
, O
and O
cell O
transformation O
. O

In O
Exp _RARE_
. O

Human I-GENE
brain O
cDNA I-GENE
library O
screening O
and O
5 I-GENE
' O
rapid O
amplification O
of O
cDNA I-GENE
ends O
yielded O
full I-GENE
- I-GENE
length I-GENE
DENTT _RARE_
cDNA I-GENE
containing O
an O
1899 _RARE_
- I-GENE
bp O
open O
reading O
frame O
encoding O
a O
predicted O
633 _RARE_
- I-GENE
amino O
- I-GENE
acid I-GENE
protein I-GENE
with O
four O
potential O
nuclear I-GENE
localization O
signals O
( O
NLSs _RARE_
) O
and O
two O
coiled O
- I-GENE
coil O
regions O
. O

NaeI _RARE_
, O
a O
novel O
DNA I-GENE
endonuclease I-GENE
, O
shows O
topoisomerase I-GENE
and O
recombinase _RARE_
activities O
when O
a O
Lys O
residue O
is O
substituted O
for O
Leu _RARE_
43 _RARE_
. O

We O
used O
a O
rev _RARE_
- I-GENE
and O
RRE _RARE_
- I-GENE
defective O
HIV I-GENE
type I-GENE
1 I-GENE
( O
HIV I-GENE
- I-GENE
1 I-GENE
) O
molecular O
clone O
in O
complementation O
experiments O
to O
establish O
a O
method O
for O
the O
rapid O
isolation O
of O
posttranscriptional O
regulatory I-GENE
elements I-GENE
from O
the O
mammalian I-GENE
genome O
by O
selecting _RARE_
for O
rescue O
of O
virus I-GENE
replication O
. O

OBJECTIVES O
: O
The O
objective O
of O
this O
review O
was O
to O
compare O
the O
effectiveness O
, O
safety O
and O
acceptability _RARE_
of O
the O
diaphragm O
with O
and O
without O
spermicide _RARE_
. O

DESIGN O
: O
Retrospective _RARE_
study O
. O

Considering _RARE_
that O
the O
reactor _RARE_
is O
thoroughly _RARE_
mixed O
during O
each O
discharge O
and O
that O
LD50 O
= O
0 O
. O
9 O
values O
are O
nearly O
independent O
of O
E I-GENE
. O
coli I-GENE
concentrations O
in O
the O
range O
of O
2 I-GENE
x O
10 O
( O
3 I-GENE
) O
< O
or O
= O
E I-GENE
coli I-GENE
/ I-GENE
cfu _RARE_
mL O
(- O
1 I-GENE
) O
< O
or O
= O
3 I-GENE
x O
10 O
( O
6 I-GENE
), O
we O
ascribe _RARE_
the O
nonexponential _RARE_
Pn _RARE_
decay O
of O
single O
- I-GENE
strain O
E I-GENE
. O
coli I-GENE
colonies O
to O
a O
shielding _RARE_
phenomenon O
where O
inactive O
cells O
protect O
the O
successively _RARE_
smaller O
numbers O
of O
viable O
cells O
in O
the O
EHD _RARE_
. O

These O
genes I-GENE
encode O
a O
tryptophanyl _RARE_
tRNA I-GENE
, O
the O
protein I-GENE
translocase _RARE_
component O
SecE _RARE_
, O
the O
antiterminator _RARE_
protein I-GENE
NusG _RARE_
, O
and O
the O
ribosomal I-GENE
proteins I-GENE
L11 _RARE_
and O
L1 I-GENE
in O
addition O
to O
PkwR _RARE_
, O
a O
putative O
regulatory I-GENE
protein I-GENE
of O
the O
LacI _RARE_
- I-GENE
GalR _RARE_
family I-GENE
. O

Body _RARE_
fat O
distribution O
was O
determined O
by O
abdominal O
computed O
tomography O
. O

The O
telomerase I-GENE
RNA I-GENE
- I-GENE
protein I-GENE
complex I-GENE
responsible O
for O
maintenance O
of O
telomeric O
DNA I-GENE
at O
chromosome O
ends O
, O
is O
usually O
inactive O
in O
most O
primary O
somatic O
human I-GENE
cells O
, O
but O
is O
specifically O
activated I-GENE
with O
in O
vitro O
immortalization _RARE_
and O
during O
tumorigenesis O
. O

This O
is O
a O
challenging _RARE_
task O
insofar _RARE_
as O
direct O
measures O
of O
ISF _RARE_
glucose I-GENE
are O
not O
readily O
available O
. O

SELECTION _RARE_
CRITERIA _RARE_
: O
All O
randomised O
controlled O
trials O
comparing O
IUSs _RARE_
with O
other O
forms O
of O
reversible O
contraceptives _RARE_
and O
reporting _RARE_
on O
pre I-GENE
- I-GENE
determined O
outcomes O
in O
women O
of O
reproductive O
years O
. O

There O
was O
a O
statistically O
significant O
correlation O
between O
simultaneous O
weekly O
average O
pollen O
levels O
in O
Philadelphia _RARE_
and O
in O
Cherry _RARE_
Hill _RARE_
( O
Acer _RARE_
, O
r O
( O
p O
) O
= O
0 O
. O
987 _RARE_
, O
Quercus _RARE_
, O
r O
( O
p O
) O
= O
0 O
. O
645 _RARE_
, O
Betula _RARE_
, O
r O
( O
p O
) O
= O
0 O
. O
896 _RARE_
, O
Pinus _RARE_
, O
r O
( O
p O
) O
= O
0 O
. O
732 _RARE_
, O
Cupressaceae _RARE_
, O
r O
( O
p O
) O
= O
0 O
. O
695 _RARE_
, O
Poaceae _RARE_
, O
r O
( O
p O
) O
= O
0 O
. O
950 _RARE_
, O
Ambrosia _RARE_
, O
r O
( O
p O
) O
= O
0 O
. O
903 _RARE_
, O
and O
Rumex _RARE_
, O
r O
( O
p O
) O
= O
0 O
. O
572 _RARE_
, O
P I-GENE
< O
0 O
. O
001 O
). O

Through _RARE_
two O
novel O
mechanisms O
, O
Arf _RARE_
inhibits O
the O
oncoprotein _RARE_
Hdm2 _RARE_
, O
a O
negative O
regulator I-GENE
of O
p53 I-GENE
. O

2 I-GENE
: O
The O
dynamic O
moduli _RARE_
of O
microcrystalline _RARE_
cellulose _RARE_
. O

Such O
knowledge O
could O
advance _RARE_
diagnosis O
and O
treatment O
of O
the O
patient O
and O
counseling _RARE_
of O
the O
affected O
family I-GENE
. O

Here O
we O
show O
that O
independent O
of O
uncertainties _RARE_
in O
the O
models O
, O
terrestrial _RARE_
planets _RARE_
with O
dense _RARE_
atmosphere _RARE_
like I-GENE
Venus _RARE_
can O
evolve _RARE_
into O
one O
of O
only O
four O
possible O
rotation _RARE_
states O
. O

Our O
results O
suggest O
that O
WASP _RARE_
activates O
transcription I-GENE
following O
TCR I-GENE
stimulation O
in O
a O
manner O
that O
is O
independent O
of O
its O
role O
in O
Arp2 _RARE_
/ I-GENE
3 I-GENE
- I-GENE
directed O
actin I-GENE
polymerization _RARE_
. O

In O
contrast O
, O
the O
ubiquitous O
expression O
of O
p19 _RARE_
( O
INK4d _RARE_
) O
has O
not O
been O
previously O
described O
in O
human I-GENE
or O
murine I-GENE
B I-GENE
- I-GENE
lineage O
cells O
. O

This O
animal O
model O
of O
dystonia _RARE_
appears O
to O
be O
a O
model O
of O
NAD _RARE_
in O
man O
from O
the O
viewpoint _RARE_
of O
treatment O
- I-GENE
response I-GENE
. O

These O
results O
indicate O
that O
evaluation O
of O
exposure O
to O
S I-GENE
. O
neurona _RARE_
by O
WB _RARE_
analysis O
of O
serum I-GENE
may O
be O
misleading _RARE_
in O
young O
horses O
. O

The O
Delta6CCI _RARE_
virus I-GENE
was O
extremely O
attenuated O
in O
replication O
capacity O
yet O
retained O
infectiousness _RARE_
for O
CEMx174 _RARE_
and O
MT4 _RARE_
cells O
. O

OBJECTIVE O
: O
To O
determine O
the O
association O
of O
depressive _RARE_
symptoms O
with O
HIV I-GENE
- I-GENE
related I-GENE
mortality O
and O
decline O
in O
CD4 I-GENE
lymphocyte I-GENE
counts O
among O
women O
with O
HIV I-GENE
. O

Phase O
II I-GENE
study O
of O
paclitaxel _RARE_
and O
oral O
etoposide _RARE_
in O
patients O
with O
locally O
advanced O
or O
metastatic O
non O
- I-GENE
small I-GENE
cell O
lung O
cancer O
. O

Analyses _RARE_
revealed O
that O
scale O
matters _RARE_
above O
and O
beyond O
the O
effect O
of O
quadrat _RARE_
area O
. O

Rind _RARE_
et O
al O
.' _RARE_
s O
study O
' O
s O
main O
conclusions O
were O
not O
supported O
by O
the O
original O
data O
. O

Not _RARE_
Available _RARE_

Lactate _RARE_
accumulation O
peak O
was O
unaffected O
by O
supplementation O
( O
HMB _RARE_
, O
8 I-GENE
. O
1 I-GENE
+/- O
1 I-GENE
. O
1 I-GENE
mM O
; O
LEU _RARE_
, O
6 I-GENE
. O
2 I-GENE
+/- O
0 O
. O
8 I-GENE
mM O
; O
CON _RARE_
, O
7 O
. O
5 I-GENE
+/- O
1 I-GENE
. O
3 I-GENE
mM O
). O

However O
, O
the O
abi1 _RARE_
- I-GENE
1 I-GENE
gene I-GENE
product I-GENE
has O
no O
effect O
on O
the O
ABA _RARE_
suppression O
of O
a O
GA _RARE_
- I-GENE
responsive I-GENE
alpha I-GENE
- I-GENE
amylase I-GENE
gene I-GENE
. O

Polyclonal _RARE_
antibodies I-GENE
against O
the O
N I-GENE
- I-GENE
terminal I-GENE
part O
( O
amino O
acids O
12 O
- I-GENE
363 _RARE_
) O
and O
the O
C I-GENE
- I-GENE
terminal I-GENE
part O
( O
amino O
acids O
330 _RARE_
- I-GENE
730 _RARE_
) O
of O
rainbow _RARE_
trout _RARE_
HIF I-GENE
- I-GENE
1alpha I-GENE
protein I-GENE
recognized O
rainbow _RARE_
trout _RARE_
and O
chinook _RARE_
salmon _RARE_
HIF I-GENE
- I-GENE
1alpha I-GENE
protein I-GENE
in O
Western O
blot O
analysis O
. O

Southern O
blot O
analysis O
of O
genomic O
DNA I-GENE
from O
somatic O
cell O
hybrids O
showed O
that O
endothelial I-GENE
- I-GENE
TACC _RARE_
- I-GENE
related I-GENE
cDNA I-GENE
maps O
to O
chromosome O
10 O
. O

PABP _RARE_
is O
a O
modular _RARE_
protein I-GENE
, O
with O
four O
N I-GENE
- I-GENE
terminal I-GENE
RNA I-GENE
- I-GENE
binding I-GENE
domains I-GENE
and O
an O
extensive O
C I-GENE
terminus O
. O

9 O
. O
7 O
( O
95 O
% O
CI O
: O
9 O
. O
6 I-GENE
- I-GENE
9 O
. O
7 O
) O
micromol _RARE_
/ I-GENE
L I-GENE
among O
women O
( O
P I-GENE
= O
0 O
. O
003 _RARE_
). O

The O
mean O
waiting _RARE_
time O
to O
receive O
the O
pancreas O
transplant O
was O
244 _RARE_
days O
for O
SPK _RARE_
and O
167 _RARE_
days O
for O
PAK _RARE_
recipients O
( O
P I-GENE
= O
0 O
. O
001 O
). O

Zarix _RARE_
expected O
patient O
enrollment _RARE_
in O
Canadian _RARE_
clinical O
sites I-GENE
to O
begin O
in O
Spring _RARE_
2001 _RARE_
[ O
397955 _RARE_
], O
[ O
405928 _RARE_
]. O

The O
isoform I-GENE
, O
designated O
HDAC9a _RARE_
, O
is O
132 O
aa O
shorter O
at O
the O
C I-GENE
terminus O
than O
HDAC9 _RARE_
. O

Long _RARE_
- I-GENE
range O
comparison O
of O
human I-GENE
and O
mouse I-GENE
SCL _RARE_
loci I-GENE
: O
localized O
regions O
of O
sensitivity O
to O
restriction O
endonucleases _RARE_
correspond O
precisely O
with O
peaks O
of O
conserved O
noncoding O
sequences I-GENE
. O

In O
Saccharomyces I-GENE
cerevisiae I-GENE
, O
eIF6 _RARE_
is O
encoded I-GENE
by O
a O
single O
- I-GENE
copy O
essential O
gene I-GENE
. O

Three O
patients O
received O
additional O
cycles O
of O
5 I-GENE
- I-GENE
fluorouracil O
+/- O
leucovorin _RARE_
as O
maintenance O
chemotherapy O
. O
RESULTS O
: O
Thirty O
males O
and O
21 O
females O
with O
a O
median O
age O
of O
55 O
years O
( O
range O
31 O
-- O
73 O
years O
) O
were O
treated O
. O

RESULTS O
: O
Within O
7 O
days O
, O
all O
groups O
re O
- I-GENE
acquired O
responding O
for O
heroin _RARE_
under O
CRF _RARE_
at O
rates O
similar O
to O
their O
pre I-GENE
- I-GENE
lesion O
performance O
. O

The O
application O
of O
the O
biotechnology _RARE_
at O
the O
plants O
for O
treatment O
of O
the O
surface I-GENE
storm _RARE_
waters _RARE_
from O
the O
industrial _RARE_
zone O
Telychka _RARE_
of O
the O
city _RARE_
of O
Kyiv _RARE_
has O
allowed O
the O
content O
of O
petroleum _RARE_
in O
water O
dropped _RARE_
to O
the O
Dnieper _RARE_
to O
be O
constantly _RARE_
reduced O
50 O
- I-GENE
100 O
times O
. O

Using O
immunochemical _RARE_
co O
- I-GENE
precipitation O
methods O
, O
we O
also O
found O
that O
the O
two O
proteins I-GENE
are O
bound O
in O
vivo O
. O

Utility _RARE_
of O
OAE _RARE_
screener _RARE_
( O
GSI _RARE_
70 I-GENE
) O
for O
the O
evaluation O
of O
distortion _RARE_
product I-GENE
otoacoustic _RARE_
emissions _RARE_
] O
The O
purpose O
of O
this O
study O
was O
to O
investigate O
the O
ability O
of O
the O
OAE _RARE_
screener _RARE_
GSI _RARE_
70 I-GENE
to O
evaluate O
of O
cochlea _RARE_
function O
in O
neonates O
, O
infants O
and O
adults O
. O

Our O
results O
demonstrated O
that O
50 O
% O
of O
the O
hepatic _RARE_
artery O
- I-GENE
alone O
ALT _RARE_
graft O
showed O
almost O
normal O
structure O
histologically O
at O
1 I-GENE
month O
after O
grafting _RARE_
, O
with O
bile O
secretion O
preserved _RARE_
. O

Mean O
Hg O
concentrations O
in O
the O
livers _RARE_
of O
mice O
at O
some O
sites I-GENE
in O
Isle _RARE_
Royale _RARE_
are O
not O
significantly O
lower O
( O
P I-GENE
= O
0 O
. O
62 O
) O
than O
Hg O
concentrations O
considered O
by O
some O
government _RARE_
agencies _RARE_
to O
be O
unhealthy _RARE_
for O
human I-GENE
consumption O
. O

We O
show O
here O
that O
the O
in O
vitro O
transcription I-GENE
extract O
contains O
a O
binding I-GENE
activity O
that O
is O
specific I-GENE
for O
the O
initiator O
element I-GENE
and O
thus O
may O
participate O
in O
recruiting _RARE_
RNA I-GENE
polymerase I-GENE
II I-GENE
to O
the O
SL _RARE_
RNA I-GENE
gene I-GENE
promoter I-GENE
. O

The O
desirability _RARE_
function O
is O
based O
on O
the O
search O
for O
a O
global O
optimum _RARE_
[ O
D I-GENE
= O
f I-GENE
( O
Y1 _RARE_
, O
Y2 _RARE_
, O
..., _RARE_
Yn _RARE_
)] O
by O
the O
transformation O
of O
the O
measured O
property _RARE_
to O
a O
dimensionless _RARE_
scale O
for O
each O
criterion O
. O

Naltrexone _RARE_
hydrochloride _RARE_
is O
a O
synthetic O
opioid _RARE_
receptor I-GENE
antagonist O
recently O
used O
in O
efforts _RARE_
to O
provide O
rapid O
opioid _RARE_
detoxification _RARE_
. O

We O
mapped O
the O
DGCR6 _RARE_
gene I-GENE
to O
chromosome O
22q11 _RARE_
within O
a O
low O
copy O
repeat I-GENE
, O
termed O
sc11 _RARE_
. O
1a I-GENE
, O
and O
identified O
a O
second O
copy O
of O
the O
gene I-GENE
, O
DGCR6L _RARE_
, O
within O
the O
duplicate _RARE_
locus I-GENE
, O
termed O
sc11 _RARE_
. O
1b I-GENE
. O

Proliferative _RARE_
vasculopathy _RARE_
and O
cutaneous O
hemorrhages _RARE_
in O
porcine _RARE_
neonates O
infected O
with O
the O
porcine _RARE_
reproductive O
and O
respiratory O
syndrome O
virus I-GENE
. O

The O
child O
left O
behind O
. O

Using O
the O
two O
- I-GENE
hybrid O
system O
, O
we O
show O
that O
nonprenylated _RARE_
Rac1 I-GENE
interacts O
very O
weakly O
with O
Rho I-GENE
- I-GENE
GDI _RARE_
, O
pointing _RARE_
to O
the O
predominant O
role O
of O
protein I-GENE
- I-GENE
isoprene _RARE_
interaction O
in O
complex I-GENE
formation O
. O

In O
contrast O
, O
neither O
I I-GENE
. O
argentina _RARE_
nor O
I I-GENE
. O
theezans _RARE_
exerted _RARE_
any O
effect O
on O
BF _RARE_
or O
intestinal O
propulsion _RARE_
. O

The O
region I-GENE
containing O
both O
serines _RARE_
is O
homologous I-GENE
to O
the O
N I-GENE
- I-GENE
terminal I-GENE
destruction _RARE_
box I-GENE
of O
IkappaBalpha I-GENE
, O
- I-GENE
beta I-GENE
, O
and O
- I-GENE
epsilon I-GENE
. O

No O
dominant I-GENE
clinical O
factor I-GENE
of O
risk O
was O
found O
, O
but O
multiple O
regression O
analysis O
identified O
age O
, O
body O
surface I-GENE
area O
, O
valve O
size O
, O
shop _RARE_
order O
fracture O
rate O
, O
and O
manufacturing _RARE_
period O
as O
risk O
factors I-GENE
for O
OSF _RARE_
. O

A I-GENE
novel O
growth I-GENE
- I-GENE
related I-GENE
nuclear I-GENE
protein I-GENE
binds O
and O
inhibits O
rat I-GENE
aldolase _RARE_
B I-GENE
gene I-GENE
promoter I-GENE
. O

Northern O
blot O
analysis O
revealed O
that O
mlt _RARE_
1 I-GENE
is O
normally O
expressed O
in O
brain O
, O
spleen O
, O
stom _RARE_
ach _RARE_
, O
and O
liver O
. O

NO O
metabolites O
were O
determined O
by O
the O
measurement O
of O
nitrate _RARE_
/ I-GENE
nitrite _RARE_
( O
NOx _RARE_
, O
micromol _RARE_
/ I-GENE
mmol O
creatinine O
) O
and O
cyclic I-GENE
guanosine _RARE_
monophosphate O
( O
cGMP _RARE_
, O
nmol O
/ I-GENE
mmol O
creatinine O
) O
in O
plasma I-GENE
and O
urine O
. O

As O
a O
complement I-GENE
to O
genome O
- I-GENE
wide O
mapping O
and O
sequencing O
efforts _RARE_
, O
it O
is O
often O
important O
to O
generate O
detailed O
maps O
and O
sequence I-GENE
data O
for O
specific I-GENE
regions O
of O
interest O
. O

The O
observed O
phenotypes O
may O
be O
explained O
by O
( O
i O
) O
a O
selective O
disruption O
of O
very O
- I-GENE
low O
- I-GENE
density I-GENE
lipoprotein I-GENE
secretion O
due O
to O
decreased O
expression O
of O
genes I-GENE
encoding O
apolipoprotein I-GENE
B I-GENE
and O
microsomal _RARE_
triglyceride _RARE_
transfer I-GENE
protein I-GENE
, O
( O
ii O
) O
an O
increase O
in O
hepatic _RARE_
cholesterol I-GENE
uptake O
due O
to O
increased O
expression O
of O
the O
major I-GENE
high O
- I-GENE
density I-GENE
lipoprotein I-GENE
receptor I-GENE
, O
scavenger _RARE_
receptor I-GENE
BI _RARE_
, O
and O
( O
iii O
) O
a O
decrease O
in O
bile O
acid I-GENE
uptake O
to O
the O
liver O
due O
to O
down O
- I-GENE
regulation O
of O
the O
major I-GENE
basolateral _RARE_
bile O
acid I-GENE
transporters I-GENE
sodium O
taurocholate _RARE_
cotransporter _RARE_
protein I-GENE
and O
organic O
anion _RARE_
transporter I-GENE
protein I-GENE
1 I-GENE
. O

Effects O
of O
aerosol _RARE_
- I-GENE
vapor _RARE_
JP _RARE_
- I-GENE
8 I-GENE
jet _RARE_
fuel _RARE_
on O
the O
functional O
observational _RARE_
battery O
, O
and O
learning O
and O
memory O
in O
the O
rat I-GENE
. O

In O
mouse I-GENE
, O
Mmip1 _RARE_
( O
Mad _RARE_
member O
interacting _RARE_
protein I-GENE
1 I-GENE
) O
and O
Smc3 _RARE_
share O
99 O
% O
sequence I-GENE
identity O
and O
are O
products I-GENE
of O
the O
same O
gene I-GENE
. O

To O
identify O
the O
important O
cis O
- I-GENE
DNA I-GENE
regulatory I-GENE
element I-GENE
( O
s O
) O
involved O
in O
the O
tissue I-GENE
-, _RARE_
region I-GENE
-, _RARE_
and O
cell O
- I-GENE
specific I-GENE
expression O
of O
the O
mE _RARE_
- I-GENE
RABP _RARE_
gene I-GENE
, O
the O
5 I-GENE
- I-GENE
kb O
DNA I-GENE
fragment I-GENE
was O
sequenced O
. O

Regional _RARE_
blood O
blow _RARE_
was O
measured O
by O
means O
of O
microspheres O
in O
predefined _RARE_
regions O
of O
the O
C6 _RARE_
, O
T11 _RARE_
, O
and O
L6 _RARE_
vertebrae _RARE_
. O

Breast _RARE_
cancer O
risk O
assessment O
: O
Who _RARE_
holds _RARE_
the O
magic _RARE_
crystal O
ball _RARE_
? O

The O
frameshift O
initiated O
by O
ADEx2 _RARE_
is O
believed O
to O
alter O
the O
regular O
coding O
sequence I-GENE
, O
acting O
as O
a O
loss O
- I-GENE
of O
- I-GENE
function O
ASIP _RARE_
mutation I-GENE
. O

CONCLUSIONS O
: O
Adding _RARE_
MMF _RARE_
, O
a O
potent O
topical _RARE_
corticosteroid _RARE_
, O
to O
an O
emollient _RARE_
cream O
is O
statistically O
significantly O
more O
effective O
than O
emollient _RARE_
cream O
alone O
in O
reducing O
acute O
radiation O
dermatitis O
. O

Copyright O
2001 _RARE_
Academic O
Press O
. O

CONCLUSIONS O
: O
Although O
the O
levels O
of O
oxLDL _RARE_
antibodies I-GENE
might O
be O
modified O
in O
early I-GENE
hypertension O
, O
once O
advanced O
coronary O
artery O
disease O
has O
developed O
the O
presence O
of O
hypertension O
does O
not O
affect O
anti I-GENE
- I-GENE
oxLDL _RARE_
levels O
. O

As O
an O
application O
of O
reverse I-GENE
genetics _RARE_
, O
we O
introduced O
one O
nucleotide I-GENE
change O
( O
UCU _RARE_
to O
ACU _RARE_
) O
to O
immediate I-GENE
downstream O
of O
the O
RNA I-GENE
- I-GENE
editing _RARE_
site I-GENE
of O
the O
V I-GENE
gene I-GENE
in O
the O
full I-GENE
- I-GENE
length I-GENE
hPIV2 _RARE_
cDNA I-GENE
and O
were O
able O
to O
obtain O
infectious O
viruses O
[ O
rPIV2V _RARE_
(-)] _RARE_
from O
the O
cDNA I-GENE
. O

At O
both O
companies _RARE_
sites I-GENE
Salmonella _RARE_
enteritidis _RARE_
and O
Salmonella _RARE_
typhimurium _RARE_
Tr104 _RARE_
were O
also O
isolated O
occasionally _RARE_
from O
various O
locations O
. O

Most O
yeast I-GENE
peroxisomal _RARE_
matrix _RARE_
proteins I-GENE
contain O
a O
type I-GENE
1C _RARE_
- I-GENE
terminal I-GENE
peroxisomal _RARE_
targeting O
signal I-GENE
( O
PTS1 _RARE_
) O
consisting O
of O
the O
tripeptide _RARE_
SKL _RARE_
or O
a O
conservative O
variant I-GENE
thereof _RARE_
. O

Tumor I-GENE
- I-GENE
like I-GENE
accumulation O
on O
Tl O
- I-GENE
201 O
SPECT O
in O
subacute O
hemorrhagic O
cerebral O
infarction O
. O

WRN _RARE_
helicase I-GENE
resolves _RARE_
alternate O
DNA I-GENE
structures O
including O
tetraplex _RARE_
and O
triplex _RARE_
DNA I-GENE
, O
and O
Holliday _RARE_
junctions O
. O

The O
increase O
in O
number O
of O
terminal I-GENE
hairs _RARE_
, O
which O
are O
defined O
as O
hairs _RARE_
more O
than O
60 O
microm O
in O
diameter O
, O
in O
the O
designated O
area O
( O
0 O
. O
5 I-GENE
cm O
square O
= O
0 O
. O
25 O
cm2 O
area O
) O
of O
the O
procyanidin _RARE_
B I-GENE
- I-GENE
2 I-GENE
group O
subjects O
after O
the O
6 I-GENE
- I-GENE
month O
trial O
was O
significantly O
greater O
than O
that O
of O
the O
placebo O
control O
group O
subjects O
( O
procyanidin _RARE_
B I-GENE
- I-GENE
2 I-GENE
, O
1 I-GENE
. O
99 O
+/- O
2 I-GENE
. O
58 O
( O
mean O
+/- O
SD O
)/ O
0 O
. O
25 O
cm2 O
; O
placebo O
, O
- I-GENE
0 O
. O
82 O
+/- O
3 I-GENE
. O
40 I-GENE
( O
mean O
+/- O
SD O
)/ O
0 O
. O
25 O
cm2 O
; O
P I-GENE
< O
0 O
. O
02 O
, O
two O
- I-GENE
sample O
t I-GENE
test O
). O

SKP1 _RARE_
- I-GENE
SnRK _RARE_
protein I-GENE
kinase I-GENE
interactions O
mediate O
proteasomal _RARE_
binding I-GENE
of O
a O
plant O
SCF _RARE_
ubiquitin I-GENE
ligase I-GENE
. O

Based O
on O
the O
hypothesis O
that O
evolutionarily O
conserved O
regions O
are O
functionally O
important O
and O
likely O
to O
interact O
with O
coactivators _RARE_
, O
we O
compared O
the O
amino O
acid I-GENE
sequence I-GENE
of O
C I-GENE
/ I-GENE
EBPalpha _RARE_
from O
different O
species O
( O
frog _RARE_
to O
human I-GENE
) O
and O
identified O
four O
highly O
conserved O
regions O
( O
CR1 _RARE_
- I-GENE
CR4 _RARE_
) O
within O
the O
transactivation O
domain I-GENE
. O

Colorectal _RARE_
cancer O
was O
shown O
to O
disproportionately _RARE_
overburden _RARE_
Ashkenazi _RARE_
Jews _RARE_
, O
who O
may O
also O
be O
at O
increased O
risk O
for O
ovarian O
, O
pancreatic O
and O
stomach O
cancer O
, O
and O
non O
- I-GENE
Hodgkin O
' O
s O
lymphoma O
. O

Percentages _RARE_
of O
recovery O
for O
overload O
and O
dilution O
tests O
were O
between O
87 O
and O
120 O
%. O

This O
shows O
that O
in O
situations O
of O
separated O
breaks _RARE_
, O
NHEJ _RARE_
deficiency O
leads O
to O
genomic O
rearrangements O
, O
in O
agreement O
with O
chromosomal I-GENE
studies O
. O

Copyright O
2001 _RARE_
S I-GENE
. O

After O
nerve I-GENE
injury O
, O
the O
nociceptive _RARE_
responses O
through O
type I-GENE
I I-GENE
neurons O
, O
which O
are O
polymodal _RARE_
C I-GENE
- I-GENE
fibers O
and O
drive O
NK1 _RARE_
- I-GENE
receptor I-GENE
mechanisms O
in O
spinal O
pain O
transmission O
, O
were O
completely O
lost O
, O
but O
without O
changes O
in O
type I-GENE
II I-GENE
ones O
, O
which O
are O
polymodal _RARE_
C I-GENE
- I-GENE
fibers O
and O
drive O
NMDA _RARE_
receptor I-GENE
- I-GENE
mechanisms O
, O
while O
type I-GENE
III I-GENE
ones O
, O
which O
are O
capsaicin _RARE_
- I-GENE
insensitive _RARE_
( O
possibly O
A I-GENE
- I-GENE
fibers O
) O
and O
drive O
NMDA _RARE_
- I-GENE
receptor I-GENE
mechanisms O
, O
were O
markedly O
enhanced O
. O

SV1 _RARE_
has O
a O
33 O
- I-GENE
amino O
acid I-GENE
insert O
in O
the O
S1 I-GENE
transmembrane I-GENE
domain I-GENE
that O
does O
not O
alter O
S1 I-GENE
overall O
hydrophobicity _RARE_
, O
but O
makes O
the O
S0 _RARE_
- I-GENE
S1 I-GENE
linker _RARE_
longer O
. O

A I-GENE
variety O
of O
receptor I-GENE
- I-GENE
mediated O
signaling O
pathways O
are O
controlled O
by O
both O
positive O
and O
negative O
extracellular I-GENE
regulators O
. O

A I-GENE
20 O
- I-GENE
base O
pair O
oligonucleotide _RARE_
containing O
this O
nonamer _RARE_
confers O
up O
- I-GENE
regulation O
by O
hypoxia O
and O
inhibition O
by O
unsaturated _RARE_
fatty I-GENE
acids O
when O
placed O
upstream I-GENE
of O
a O
heterologous O
promoter I-GENE
in O
a O
lacZ I-GENE
reporter I-GENE
construct I-GENE
. O

Our O
results O
indicate O
that O
D I-GENE
( O
4 I-GENE
) O
and O
D I-GENE
( O
2L _RARE_
) O
receptors I-GENE
activate O
the O
ERK I-GENE
kinase I-GENE
cascade O
by O
first O
mobilizing _RARE_
signaling O
by O
the O
PDGF I-GENE
receptor I-GENE
, O
followed O
by O
the O
subsequent O
activation O
of O
ERK1 I-GENE
/ I-GENE
2 I-GENE
by O
pathways O
associated I-GENE
with O
this O
receptor I-GENE
tyrosine I-GENE
kinase I-GENE
. O

Raes _RARE_
, O
P I-GENE
. O

Finally O
, O
we O
compared O
the O
differential O
screening O
techniques O
in O
terms O
of O
sensitivity O
, O
efficiency O
and O
occurrence O
of O
false O
positives _RARE_
. O

C I-GENE
/ I-GENE
EBPbeta I-GENE
LIP _RARE_
overexpressing O
HC11 _RARE_
cells O
did O
not O
express O
beta I-GENE
- I-GENE
casein I-GENE
mRNA I-GENE
( O
mammary O
epithelial O
cell O
differentiation O
marker O
) O
in O
response I-GENE
to O
lactogenic _RARE_
hormones O
. O

NF I-GENE
- I-GENE
kappaB I-GENE
is O
involved O
in O
the O
regulation O
of O
CD154 _RARE_
( O
CD40 I-GENE
ligand O
) O
expression O
in O
primary O
human I-GENE
T I-GENE
cells O
. O

Subacute _RARE_
diencephalic _RARE_
angioencephalopathy _RARE_
( O
SDAE _RARE_
) O
is O
a O
rare O
and O
fatal O
disease O
of O
unknown O
etiology O
that O
involves O
the O
thalami _RARE_
bilaterally _RARE_
. O

NGF _RARE_
elicits _RARE_
a O
more O
delayed O
and O
sustained O
ERK I-GENE
phosphorylation O
than O
EGF I-GENE
, O
consistent O
with O
previous O
reports O
. O

TBARS _RARE_
levels O
, O
oxygen O
- I-GENE
radical O
absorbing _RARE_
capacity O
assay O
and O
AFR _RARE_
release O
assessed O
by O
electron O
paramagnetic _RARE_
resonance O
( O
EPR _RARE_
) O
were O
used O
to O
explore O
the O
existence O
of O
oxidative O
stress I-GENE
in O
diabetes O
. O

Pulmonary _RARE_
vein O
varix _RARE_
in O
association O
with O
bilateral O
pulmonary O
vein O
stenosis O
. O

Derivation _RARE_
and O
initial O
characterization O
of O
a O
mouse I-GENE
mammary O
tumor I-GENE
cell O
line O
carrying O
the O
polyomavirus _RARE_
middle _RARE_
T I-GENE
antigen I-GENE
: O
utility _RARE_
in O
the O
development O
of O
novel O
cancer O
therapeutics _RARE_
. O

The O
images O
showed O
rapid O
, O
predominantly O
urinary O
excretion O
of O
99mTc O
ciprofloxacin _RARE_
, O
with O
low O
to O
absent O
brain O
, O
lung O
and O
bone O
marrow O
uptake O
and O
low O
liver O
uptake O
and O
excretion O
. O

Thus O
, O
the O
anti I-GENE
- I-GENE
interferon I-GENE
functions O
of O
vIRF _RARE_
- I-GENE
2 I-GENE
may O
contribute O
to O
the O
establishment O
of O
a O
chronic O
or O
latent I-GENE
infection O
. O

Topological _RARE_
and O
mutational O
analysis O
of O
Saccharomyces I-GENE
cerevisiae I-GENE
Ste14p _RARE_
, O
founding _RARE_
member O
of O
the O
isoprenylcysteine _RARE_
carboxyl O
methyltransferase I-GENE
family I-GENE
. O

Two O
remotely _RARE_
situated O
exons O
within O
the O
complement I-GENE
C3 I-GENE
gene I-GENE
locus I-GENE
encode O
an O
alternate O
5 I-GENE
' O
end O
and O
proximal I-GENE
ORF I-GENE
under O
the O
control O
of O
a O
bidirectional _RARE_
promoter I-GENE
. O

Although O
there O
was O
a O
high O
correlation O
between O
sap _RARE_
flux _RARE_
densities _RARE_
registered _RARE_
by O
the O
old O
and O
new O
sensors _RARE_
, O
significant O
differences O
in O
sap _RARE_
flux _RARE_
densities _RARE_
between O
the O
duplicated O
sensors _RARE_
were O
detected O
. O

Their O
numbers O
have O
regularly _RARE_
increased O
since O
the O
mid O
- I-GENE
1970s _RARE_
. O

The O
hcKrox _RARE_
gene I-GENE
family I-GENE
regulates O
multiple O
extracellular I-GENE
matrix _RARE_
genes I-GENE
. O

NB _RARE_
- I-GENE
506 _RARE_
completely O
inhibits O
the O
capacity O
of O
topoisomerase I-GENE
I I-GENE
to O
phosphorylate O
, O
in O
vitro O
, O
the O
human I-GENE
splicing O
factor I-GENE
2 I-GENE
/ I-GENE
alternative O
splicing O
factor I-GENE
( O
SF2 _RARE_
/ I-GENE
ASF _RARE_
). O

Recent O
studies O
using O
isolated O
rat I-GENE
adipocytes O
and O
chemically _RARE_
synthesized O
PIG _RARE_
compounds O
point O
to O
IRS1 _RARE_
/ I-GENE
3 I-GENE
tyrosine I-GENE
phosphorylation O
by O
p59Lyn _RARE_
kinase I-GENE
as O
the O
site I-GENE
of O
cross O
- I-GENE
talk _RARE_
, O
the O
negative O
regulation O
of O
which O
by O
interaction O
with O
caveolin _RARE_
is O
apparently O
abrogated O
by O
PIG _RARE_
. O

To O
investigate O
the O
effects O
of O
exogenous O
hyaluronic _RARE_
acid I-GENE
, O
the O
development O
of O
port _RARE_
- I-GENE
site I-GENE
metastasis O
was O
examined O
using O
mouse I-GENE
adenocarcinoma O
cell O
- I-GENE
line O
colon O
26 O
cells O
. O

METHODS O
: O
Thyroid _RARE_
status O
was O
measured O
at O
baseline O
( O
1990 O
- I-GENE
93 O
), O
through O
assessment O
of O
serum I-GENE
antibodies I-GENE
to O
thyroid I-GENE
peroxidase I-GENE
( O
TPO _RARE_
- I-GENE
Abs _RARE_
, O
positive O
: O
> O
10 O
IU O
/ I-GENE
ml O
), O
serum I-GENE
TSH I-GENE
levels O
, O
and O
when O
TSH I-GENE
was O
abnormal O
(< O
0 O
. O
4 I-GENE
or O
> O
4 I-GENE
. O
0 O
mU _RARE_
/ I-GENE
l O
), O
serum I-GENE
thyroxin _RARE_
levels O
( O
T4 I-GENE
). O

Mechanical _RARE_
ventilation O
in O
control O
lungs O
produced O
a O
47 O
% O
decrease O
in O
chord _RARE_
compliance O
, O
an O
increase O
in O
lung O
lavage _RARE_
levels O
of O
tumor I-GENE
necrosis I-GENE
factor I-GENE
( O
TNF I-GENE
)- I-GENE
alpha I-GENE
( O
722 _RARE_
+/- O
306 _RARE_
pg O
/ I-GENE
ml O
), O
interleukin I-GENE
( O
IL I-GENE
)- I-GENE
1beta I-GENE
( O
902 _RARE_
+/- O
322 _RARE_
pg O
/ I-GENE
ml O
), O
and O
macrophage I-GENE
inflammatory O
protein I-GENE
- I-GENE
2 I-GENE
( O
MIP _RARE_
- I-GENE
2 I-GENE
) O
( O
363 _RARE_
+/- O
104 O
pg O
/ I-GENE
ml O
) O
as O
compared O
with O
low O
levels O
of O
cytokines O
detected O
in O
preventilation _RARE_
data O
, O
and O
no O
change O
in O
percentage O
of O
surfactant _RARE_
large O
aggregates O
( O
LA O
). O

Autoregulation _RARE_
enables O
different O
pathways O
to O
control O
CCAAT I-GENE
/ I-GENE
enhancer I-GENE
binding I-GENE
protein I-GENE
beta I-GENE
( O
C I-GENE
/ I-GENE
EBP I-GENE
beta I-GENE
) O
transcription I-GENE
. O

In O
the O
past O
decade _RARE_
, O
there O
have O
been O
enormous _RARE_
advances _RARE_
in O
the O
use O
of O
Bayesian _RARE_
methodology _RARE_
for O
analysis O
of O
epidemiologic _RARE_
data O
, O
and O
there O
are O
now O
many O
practical _RARE_
advantages O
to O
the O
Bayesian _RARE_
approach O
. O

In O
strains O
lacking O
tup11 _RARE_
and O
tup12 _RARE_
, O
the O
atf1 _RARE_
- I-GENE
pcr1 _RARE_
transcriptional O
activator I-GENE
continues _RARE_
to O
play O
a O
central O
role O
in O
fbp1 _RARE_
- I-GENE
lacZ I-GENE
expression O
; O
however O
, O
spc1 _RARE_
MAPK I-GENE
phosphorylation O
of O
atf1 _RARE_
is O
no O
longer O
essential O
for O
its O
activation O
. O

Single _RARE_
amino O
acid I-GENE
substitutions O
at O
the O
acyl _RARE_
- I-GENE
CoA I-GENE
- I-GENE
binding I-GENE
domain I-GENE
interrupt _RARE_
14 O
[ O
C I-GENE
] O
palmitoyl _RARE_
- I-GENE
CoA I-GENE
binding I-GENE
of O
ACBP2 _RARE_
, O
an O
Arabidopsis I-GENE
acyl _RARE_
- I-GENE
CoA I-GENE
- I-GENE
binding I-GENE
protein I-GENE
with O
ankyrin _RARE_
repeats I-GENE
. O

RESULTS O
: O
Sixty _RARE_
per O
cent O
of O
African O
Americans _RARE_
exposed O
in O
26 O
community O
outbreaks _RARE_
were O
TST _RARE_
positive O
compared O
to O
only O
40 I-GENE
% O
of O
whites _RARE_
following O
comparable O
exposures O
. O

For O
immunological _RARE_
methods O
, O
identification O
of O
such O
antigens I-GENE
with O
intermolecular _RARE_
variability O
, O
e O
. O
g O
., O
the O
structural O
aescin _RARE_
analogs _RARE_
, O
is O
of O
unknown O
validity O
. O

It O
was O
found O
that O
intrathecal _RARE_
administration O
( O
i O
. O
t I-GENE
.) O
of O
D2 I-GENE
receptor I-GENE
agonist O
LY171555 _RARE_
or O
D1 I-GENE
/ I-GENE
D2 I-GENE
receptor I-GENE
agonist O
apomorphine _RARE_
increased O
pain O
threshold O
and O
had O
a O
potentiating _RARE_
effect O
on O
AA O
. O

Interactions _RARE_
between O
the O
checkpoint _RARE_
abrogator _RARE_
UCN _RARE_
- I-GENE
01 O
and O
several O
pharmacological O
inhibitors O
of O
the O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( O
MAPK I-GENE
) O
kinase I-GENE
( O
MEK I-GENE
)/ O
MAPK I-GENE
pathway O
have O
been O
examined O
in O
a O
variety O
of O
human I-GENE
leukemia I-GENE
cell O
lines O
. O

Analysis O
of O
regulatory I-GENE
regions O
in O
the O
promoter I-GENE
of O
the O
ctr4 _RARE_
(+) _RARE_
copper _RARE_
transporter I-GENE
gene I-GENE
in O
fission _RARE_
yeast I-GENE
Schizosaccharomyces I-GENE
pombe I-GENE
reveals O
the O
identity O
of O
a O
conserved O
copper _RARE_
- I-GENE
signaling O
element I-GENE
( O
CuSE _RARE_
), O
which O
is O
recognized O
by O
the O
transcription I-GENE
factor I-GENE
Cuf1 _RARE_
. O

However O
, O
during O
our O
work O
with O
a O
replication O
- I-GENE
deficient O
virus I-GENE
expressing O
the O
ASF _RARE_
/ I-GENE
SF2 _RARE_
splicing O
factor I-GENE
from O
a O
progesterone I-GENE
antagonist O
- I-GENE
inducible I-GENE
gene I-GENE
cassette _RARE_
, O
we O
discovered O
that O
ASF _RARE_
/ I-GENE
SF2 _RARE_
was O
expressed O
at O
a O
significant O
level O
in O
the O
293 O
producer _RARE_
cell O
line O
, O
even O
in O
the O
absence O
of O
inducer _RARE_
. O

This O
study O
suggests O
that O
PSP _RARE_
is O
more O
common O
than O
previously O
considered O
, O
is O
commonly O
misdiagnosed _RARE_
and O
that O
the O
majority O
of O
cases O
are O
not O
initially O
referred O
to O
neurologists _RARE_
. O

Between _RARE_
1967 _RARE_
and O
1994 O
, O
495 _RARE_
patients O
underwent O
surgery O
for O
primary O
PTC _RARE_
at O
the O
Department _RARE_
of O
Surgery _RARE_
, O
Helsinki _RARE_
University O
Central _RARE_
Hospital _RARE_
. O

The O
described O
results O
show O
that O
DTD _RARE_
is O
fast O
, O
simple O
, O
and O
easy _RARE_
to O
automate _RARE_
; O
requires O
only O
a O
small I-GENE
amount O
of O
sample O
( O
approximately O
50 O
mg O
); O
and O
affords _RARE_
quantitative O
information O
about O
the O
main O
groups O
of O
compounds O
present O
in O
cheeses _RARE_
. O

Srb10 _RARE_
is O
a O
physiological O
regulator I-GENE
of O
Gcn4 _RARE_
stability O
because O
both O
phosphorylation O
and O
turnover O
of O
Gcn4 _RARE_
are O
diminished O
in O
srb10 _RARE_
mutants I-GENE
. O

The O
promoter I-GENE
activity O
of O
the O
proximal I-GENE
region I-GENE
was O
found O
to O
be O
restricted O
to O
a O
subset O
of O
prestalk _RARE_
cells O
. O

Two O
nuclear I-GENE
medicine O
physicians O
blinded _RARE_
to O
the O
surgical O
findings O
interpreted O
all O
available O
images O
and O
various O
Tc O
- I-GENE
99m O
MIBI _RARE_
image O
combinations O
at O
15 O
minutes O
alone O
; O
15 O
minutes O
and O
2 I-GENE
hours O
, O
15 O
minutes O
and O
4 I-GENE
hours O
; O
and O
15 O
minutes O
and O
2 I-GENE
and O
4 I-GENE
hours O
each O
with O
and O
without O
correlative _RARE_
pertechnetate _RARE_
thyroid I-GENE
imaging O
. O

We O
demonstrated O
that O
, O
under O
serum I-GENE
- I-GENE
starved _RARE_
conditions O
, O
KMS _RARE_
- I-GENE
11 I-GENE
and O
OPM _RARE_
- I-GENE
2 I-GENE
cells O
express O
appreciable _RARE_
levels O
of O
phosphorylated O
FGFR3 _RARE_
mutants I-GENE
indicating O
a O
constitutive O
activation O
of O
the O
Y373C _RARE_
and O
K650E _RARE_
receptors I-GENE
; O
the O
addition O
of O
the O
aFGF _RARE_
ligand O
further O
increased O
the O
level O
of O
receptor I-GENE
phosphorylation O
. O

Identical _RARE_
effects O
were O
obtained O
when O
inhibitors O
and O
dominant I-GENE
negative O
mutants I-GENE
were O
tested O
on O
the O
- I-GENE
29 O
to O
+ I-GENE
139 O
bp O
region I-GENE
of O
the O
cyclin I-GENE
D1 I-GENE
promoter I-GENE
. O

In O
this O
paper O
the O
tyrosine I-GENE
dephosphorylating _RARE_
enzymes O
, O
the O
protein I-GENE
- I-GENE
tyrosine I-GENE
phosphatases I-GENE
( O
PTPs _RARE_
), O
are O
studied O
which O
can O
be O
grouped _RARE_
into O
two O
subfamilies _RARE_
, O
the O
soluble _RARE_
PTPs _RARE_
and O
the O
receptor I-GENE
PTPs _RARE_
( O
RPTPs _RARE_
). O

Coexposure _RARE_
to O
FP _RARE_
also O
resulted O
in O
a O
more O
pronounced O
and O
sustained O
activation O
of O
the O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
kinase I-GENE
/ I-GENE
extracellular I-GENE
signal I-GENE
- I-GENE
regulated O
protein I-GENE
kinase I-GENE
cascade O
after O
PMA O
treatment O
, O
although O
disruption O
of O
this O
pathway O
by O
the O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
kinase I-GENE
1 I-GENE
inhibitor I-GENE
U0126 _RARE_
did O
not O
prevent O
potentiation O
of O
apoptosis O
. O

The O
LA O
50s _RARE_
derived I-GENE
from O
this O
combined O
data O
when O
compared O
with O
our O
earlier O
series O
from O
1965 _RARE_
to O
1970 _RARE_
also O
did O
not O
show O
a O
significant O
change O
in O
mortality O
. O

Most O
patients O
harboring O
metronidazole _RARE_
- I-GENE
and O
clarithromycin _RARE_
- I-GENE
resistant O
strains O
were O
eradicated _RARE_
at O
an O
equal O
rate O
by O
each O
of O
the O
three O
regimens O
. O

Responses _RARE_
of O
single O
- I-GENE
unit I-GENE
carotid O
body O
chemoreceptors _RARE_
in O
adult O
rats O
. O

Thus O
, O
MKK7 _RARE_
is O
an O
essential O
and O
specific I-GENE
regulator I-GENE
of O
stress I-GENE
- I-GENE
induced O
SAPK I-GENE
/ I-GENE
JNK I-GENE
activation O
in O
mast _RARE_
cells O
and O
MKK7 _RARE_
negatively O
regulates O
growth I-GENE
factor I-GENE
and O
antigen I-GENE
receptor I-GENE
- I-GENE
driven O
proliferation O
in O
hematopoietic I-GENE
cells O
. O

The O
N I-GENE
- I-GENE
terminal I-GENE
portion O
of O
Notch I-GENE
( O
IC _RARE_
) O
inhibited O
p50 I-GENE
DNA I-GENE
binding I-GENE
and O
interacted O
specifically O
with O
p50 I-GENE
subunit I-GENE
, O
not O
p65 I-GENE
of O
NF I-GENE
- I-GENE
kappaB I-GENE
. O

To O
account O
for O
this O
observation O
, O
other O
possible O
causes O
include O
increased O
CSF I-GENE
pulsation _RARE_
in O
children O
creating _RARE_
motion O
artifact _RARE_
, O
changes O
in O
arterial O
oxygen O
concentration O
intrinsic O
to O
propofol _RARE_
or O
related I-GENE
to O
the O
supplemental _RARE_
oxygen O
normally O
administered O
, O
or O
changes O
in O
CSF I-GENE
protein I-GENE
levels O
related I-GENE
to O
propofol _RARE_
binding I-GENE
to O
proteins I-GENE
for O
uptake O
into O
CSF I-GENE
. O

Molecular O
cloning O
and O
characterization O
of O
OsPSK _RARE_
, O
a O
gene I-GENE
encoding O
a O
precursor I-GENE
for O
phytosulfokine _RARE_
- I-GENE
alpha I-GENE
, O
required O
for O
rice _RARE_
cell O
proliferation O
. O

The O
present O
study O
was O
initiated O
to O
explore O
the O
potential O
of O
a O
hybrid O
biological O
reactor _RARE_
, O
combining _RARE_
trickling _RARE_
filter O
( O
TF I-GENE
) O
and O
activated I-GENE
sludge _RARE_
process O
( O
ASP _RARE_
), O
to O
treat O
wastewater _RARE_
containing O
trichloroethylene _RARE_
( O
TCE _RARE_
) O
at O
ambient _RARE_
temperature O
at O
different O
hydraulic _RARE_
retention O
time O
( O
HRT _RARE_
). O

If O
you _RARE_
think _RARE_
education O
is O
expensive _RARE_
-- O
try _RARE_
ignorance _RARE_
-- O
Bok _RARE_
' O
s O
Law _RARE_
. O

The O
COD _RARE_
and O
color O
removals _RARE_
were O
both O
more O
than O
90 O
% O
when O
FeCl3 _RARE_
was O
used O
as O
the O
coagulation I-GENE
( O
dosages _RARE_
of O
two O
- I-GENE
step O
coagulation I-GENE
were O
0 O
. O
031 _RARE_
and O
0 O
. O
012 _RARE_
mol O
/ I-GENE
L I-GENE
respectively O
) O
after O
a O
ferrous _RARE_
hydrogen O
peroxide _RARE_
oxidation O
pretreatment O
at O
a O
H2O2 _RARE_
dosage O
of O
0 O
. O
06 O
mol O
/ I-GENE
L I-GENE
. O

An O
element I-GENE
within O
the O
5 I-GENE
' O
untranslated O
region I-GENE
of O
human I-GENE
Hsp70 _RARE_
mRNA I-GENE
which O
acts O
as O
a O
general O
enhancer I-GENE
of O
mRNA I-GENE
translation I-GENE
. O

The O
selective O
alteration O
of O
the O
genome O
using O
Cre _RARE_
recombinase _RARE_
to O
target O
the O
rearrangement O
of O
genes I-GENE
flanked O
by O
LOX _RARE_
recognition I-GENE
sequences I-GENE
has O
required O
the O
use O
of O
two O
separate O
genetic O
constructs I-GENE
in O
trans O
, O
one O
containing O
cre _RARE_
and O
the O
other O
containing O
the O
gene I-GENE
of O
interest O
flanked O
by O
LOX _RARE_
sites I-GENE
. O

It O
has O
been O
suggested O
that O
members I-GENE
of O
this O
protein I-GENE
family I-GENE
exhibit O
both O
prolyl _RARE_
isomerase I-GENE
and O
chaperone _RARE_
activity O
. O

Newcastle _RARE_
disease O
antibody I-GENE
titre _RARE_
is O
dependent I-GENE
on O
serum I-GENE
calcium O
concentration O
. O

In O
three O
cases O
( O
21 O
. O
4 I-GENE
%), O
the O
MR O
imaging O
was O
interpreted O
as O
negative O
, O
but O
microscopic O
tumor I-GENE
was O
shown O
around O
seroma _RARE_
on O
reexcision _RARE_
. O

2 I-GENE
were O
nonviable _RARE_
, O
and O
the O
mutant I-GENE
Vp1s _RARE_
unexpectedly _RARE_
failed O
to O
localize O
to O
the O
nucleus O
though O
Vp2 _RARE_
and O
Vp3 _RARE_
did O
, O
suggesting O
that O
the O
mutated O
NLS1 _RARE_
acted _RARE_
as O
a O
dominant I-GENE
signal I-GENE
for O
the O
cytoplasmic I-GENE
localization O
of O
Vp1 _RARE_
. O

Compared _RARE_
with O
normal O
control O
subjects O
, O
all O
74 O
TOF O
patients O
had O
decreased O
systolic O
and O
diastolic O
myocardial O
velocities _RARE_
and O
a O
longer O
isovolumic _RARE_
relaxation O
time O
. O

The O
corresponding O
orifice _RARE_
voltages _RARE_
for O
the O
three O
instruments O
were O
20 O
/ I-GENE
50 O
/ I-GENE
80 O
V I-GENE
( O
API _RARE_
365 _RARE_
), O
30 O
/ I-GENE
90 O
/ I-GENE
130 _RARE_
V I-GENE
( O
API _RARE_
2000 O
) O
and O
40 I-GENE
/ I-GENE
80 O
/ I-GENE
120 O
V I-GENE
( O
API _RARE_
3000 _RARE_
). O

We O
compared O
previously O
the O
methylation O
status O
between O
normal O
liver O
and O
liver O
tumors O
in O
SV40 I-GENE
T I-GENE
/ I-GENE
t I-GENE
antigen I-GENE
transgenic O
mice O
( O
MT _RARE_
- I-GENE
D2 I-GENE
mice O
) O
using O
Restriction O
Landmark _RARE_
Genomic O
Scanning _RARE_
for O
Methylation _RARE_
( O
RLGS _RARE_
- I-GENE
M I-GENE
) O
and O
identified O
several O
loci I-GENE
/ I-GENE
spots O
that O
appeared O
to O
be O
methylated _RARE_
frequently O
in O
liver O
tumors O
. O

We O
have O
cloned O
a O
novel O
mouse I-GENE
protein I-GENE
, O
TAF I-GENE
( O
II I-GENE
) O
140 O
, O
containing O
an O
HFD _RARE_
and O
a O
plant O
homeodomain I-GENE
( O
PHD _RARE_
) O
finger I-GENE
, O
which O
we O
demonstrated O
by O
immunoprecipitation O
to O
be O
a O
mammalian I-GENE
TFIID I-GENE
component O
. O

3D _RARE_
image O
- I-GENE
processing O
permits O
to O
analyse _RARE_
ultrasound O
data O
interactively _RARE_
in O
three O
orthogonal _RARE_
planes _RARE_
( O
section O
mode O
) O
or O
in O
realistic _RARE_
3D _RARE_
views _RARE_
( O
rendering _RARE_
mode O
). O

A I-GENE
proposal _RARE_
of O
50 O
performance O
indicators O
divided O
into O
five O
different O
groups O
is O
presented O
here O
, O
namely O
structural O
indicators O
, O
operational _RARE_
indicators O
, O
water O
and O
service _RARE_
quality O
indicators O
, O
personnel _RARE_
indicators O
and O
economic _RARE_
indicators O
. O

These O
analyses O
re O
- I-GENE
open O
the O
question O
whether O
all O
the O
CesA _RARE_
genes I-GENE
encode O
cellulose _RARE_
synthases _RARE_
or O
whether O
some O
of O
the O
sub O
- I-GENE
class I-GENE
members I-GENE
may O
encode O
other O
non O
- I-GENE
cellulosic _RARE_
( O
1 I-GENE
--> O
4 I-GENE
) O
beta I-GENE
- I-GENE
glycan _RARE_
synthases _RARE_
in O
plants O
. O

The O
relationship O
of O
the O
factor I-GENE
V I-GENE
Leiden _RARE_
mutation I-GENE
or O
the O
deletion I-GENE
- I-GENE
deletion I-GENE
polymorphism O
of O
the O
angiotensin I-GENE
converting I-GENE
enzyme I-GENE
to O
postoperative O
thromboembolic _RARE_
events O
following O
total O
joint O
arthroplasty _RARE_
. O

In O
contrast O
, O
exogenous O
PTHrP1 _RARE_
- I-GENE
34 O
and O
1 I-GENE
- I-GENE
86 _RARE_
peptides I-GENE
did O
not O
significantly O
affect O
IL I-GENE
- I-GENE
8 I-GENE
production O
; O
moreover _RARE_
, O
PTHrP _RARE_
- I-GENE
neutralizing _RARE_
antibodies I-GENE
did O
not O
inhibit O
the O
production O
of O
IL I-GENE
- I-GENE
8 I-GENE
by O
transfected O
PTHrP _RARE_
. O

Furthermore O
, O
this O
kinase I-GENE
- I-GENE
deficient O
mutant I-GENE
inhibited O
2 I-GENE
- I-GENE
MeSADP _RARE_
- I-GENE
induced O
caspase _RARE_
- I-GENE
3 I-GENE
stimulation O
and O
the O
associated I-GENE
decrease O
in O
cell O
number O
. O

Against _RARE_
gram O
- I-GENE
positive O
organisms O
, O
E I-GENE
- I-GENE
4767 _RARE_
and O
E I-GENE
- I-GENE
5065 _RARE_
were O
, O
in O
general O
, O
eight O
- I-GENE
and O
fourfold O
more O
active O
than O
tosufloxacin _RARE_
, O
which O
is O
the O
most O
potent O
of O
the O
reference O
compounds O
. O

The O
results O
presented O
here O
show O
that O
AR1 _RARE_
of O
the O
promoter I-GENE
- I-GENE
proximal I-GENE
CAP _RARE_
subunit I-GENE
was O
required O
for O
papBA _RARE_
transcription I-GENE
even O
in O
the O
absence O
of O
the O
histone I-GENE
- I-GENE
like I-GENE
protein I-GENE
H I-GENE
- I-GENE
NS O
. O

CONCLUSIONS O
: O
Under O
current O
immunization O
practices _RARE_
, O
the O
authors O
estimate O
that O
nearly O
13 O
, O
000 O
Asian _RARE_
and O
Pacific _RARE_
Islander _RARE_
children O
living O
in O
the O
United O
States _RARE_
today _RARE_
will O
become O
infected O
with O
HBV O
in O
the O
future O
, O
resulting O
in O
more O
than O
600 O
liver O
carcinoma O
deaths O
. O

METHODS O
: O
A I-GENE
structured O
interview _RARE_
was O
undertaken O
at O
the O
time O
of O
initial O
consultation _RARE_
and O
at O
subsequent O
1 I-GENE
- I-GENE
year O
intervals O
regarding O
type I-GENE
of O
BHS _RARE_
, O
frequency O
of O
spells _RARE_
, O
associated I-GENE
phenomenon O
, O
sequelae _RARE_
, O
family I-GENE
history O
, O
and O
age O
at O
termination O
of O
spells _RARE_
. O

Cell O
. O

Rapid _RARE_
evolution O
of O
the O
DNA I-GENE
- I-GENE
binding I-GENE
site I-GENE
in O
LAGLIDADG _RARE_
homing _RARE_
endonucleases _RARE_
. O

These O
mutations O
, O
when O
placed O
in O
a O
wild I-GENE
- I-GENE
type I-GENE
fliF _RARE_
background O
, O
had O
no O
mutant I-GENE
phenotype O
. O

Inhibition O
of O
JNK1 I-GENE
and O
ERK I-GENE
kinase I-GENE
activities O
either O
by O
expression O
of O
the O
dominant I-GENE
negative O
mutant I-GENE
JNK1 I-GENE
or O
by O
treatment O
with O
a O
selective O
chemical O
inhibitor I-GENE
of O
ERK I-GENE
( O
PD098059 _RARE_
) O
substantially O
abrogates _RARE_
the O
UV O
induction O
of O
the O
GADD45 _RARE_
promoter I-GENE
. O

At O
termination O
( O
gd _RARE_
20 O
), O
confirmed O
- I-GENE
pregnant O
females O
( O
21 O
to O
25 O
per O
group O
) O
were O
evaluated O
for O
clinical O
status O
and O
gestational O
outcome O
; O
live O
fetuses _RARE_
were O
examined O
for O
external O
, O
visceral O
, O
and O
skeletal I-GENE
malformations O
. O

In O
mammals O
, O
the O
transcriptional O
repressors _RARE_
in O
the O
Wnt I-GENE
pathway O
are O
not O
well O
defined O
. O

Intravenous O
L I-GENE
- I-GENE
carnitine _RARE_
treatment O
increased O
plasma I-GENE
carnitine _RARE_
concentrations O
, O
improved O
patient O
- I-GENE
assessed O
fatigue _RARE_
, O
and O
may O
prevent O
the O
decline O
in O
peak O
exercise O
capacity O
in O
hemodialysis O
patients O
. O

The O
Van _RARE_
der _RARE_
Hoeve _RARE_
' O
s O
syndrome O
lesions O
as O
poorly O
mineralized _RARE_
, O
with O
low O
calcium O
salt O
and O
apparent O
increase O
of O
phosphates _RARE_
. O

A I-GENE
computerized O
method O
of O
determining O
the O
focal _RARE_
point O
of O
electrical O
activity O
in O
the O
pallidum _RARE_
of O
parkinsonian _RARE_
patients O
was O
developed O
using O
on O
- I-GENE
line O
quantitative O
physiological O
data O
analysis O
. O

The O
first O
hypothesis O
was O
supported O
in O
the O
sense O
that O
stimulus O
differences O
might O
affect O
behaviour O
even O
without O
their O
successful O
attentive _RARE_
processing O
in O
normal O
participants _RARE_
. O

We O
interpret _RARE_
these O
data O
as O
further O
evidence O
that O
interaction O
with O
a O
small I-GENE
GTPase I-GENE
is O
the O
main O
regulatory I-GENE
function O
of O
the O
C1 I-GENE
domain I-GENE
in O
yeast I-GENE
. O

This O
effect O
was O
observed O
in O
the O
absence O
of O
de O
novo _RARE_
protein I-GENE
synthesis O
and O
was O
independent O
of O
histone I-GENE
deacetylase _RARE_
activity O
. O

Mutation O
analyses O
identified O
the O
cobalt _RARE_
- I-GENE
responsive I-GENE
sequences I-GENE
as O
the O
stress I-GENE
- I-GENE
response I-GENE
elements I-GENE
( O
StREs _RARE_
). O

In O
order O
to O
quantify _RARE_
these O
effects O
, O
tests O
were O
conducted O
in O
the O
NASA _RARE_
MSFC _RARE_
Neutral _RARE_
Buoyancy _RARE_
Simulator _RARE_
, O
in O
the O
NASA _RARE_
KC _RARE_
- I-GENE
135 O
in O
parabolic _RARE_
flight _RARE_
, O
and O
in O
space O
with O
the O
EASE _RARE_
program O
during O
the O
Shuttle _RARE_
Atlantis _RARE_
mission _RARE_
61 O
- I-GENE
B I-GENE
. O

OBJECTIVE O
: O
To O
investigate O
the O
association O
between O
complete O
congenital O
heart O
block O
( O
CCHB _RARE_
) O
in O
the O
fetus O
and O
adult O
disease O
. O

The O
present O
chemotherapy O
of O
AE _RARE_
is O
based O
on O
the O
administration O
of O
benzimidazole _RARE_
carbamate _RARE_
derivatives O
, O
such O
as O
mebendazole _RARE_
and O
albendazole _RARE_
. O

The O
uptake O
of O
fluorine _RARE_
- I-GENE
18 O
fluorodeoxyglucose _RARE_
( O
F I-GENE
- I-GENE
18 O
FDG O
) O
by O
a O
malignant O
tumor I-GENE
depends O
on O
the O
blood O
glucose I-GENE
level O
. O

Deterministic _RARE_
effects O
. O

DESIGN O
: O
A I-GENE
retrospective O
chart _RARE_
review O
of O
9 O
, O
322 _RARE_
patients O
undergoing O
surgical O
procedures O
in O
the O
period O
January O
1993 O
to O
December _RARE_
1998 O
. O

Peripheral _RARE_
and O
preemptive _RARE_
opioid _RARE_
antinociception _RARE_
in O
a O
mouse I-GENE
visceral O
pain O
model O
. O

METHODS O
: O
We O
studied O
the O
clinical O
benefit O
of O
depth O
- I-GENE
dependent I-GENE
RR O
, O
nonuniform _RARE_
AC _RARE_
using O
a O
scanning O
line O
source O
, O
and O
scatter _RARE_
correction O
( O
photon O
energy O
recovery O
[ O
PER _RARE_
]) _RARE_
compared O
with O
filtered _RARE_
backprojection _RARE_
alone O
. O

Cloning O
and O
characterization O
of O
the O
murine I-GENE
beta I-GENE
( O
3 I-GENE
) O
integrin I-GENE
gene I-GENE
promoter I-GENE
: O
identification O
of O
an O
interleukin I-GENE
- I-GENE
4 I-GENE
responsive I-GENE
element I-GENE
and O
regulation O
by O
STAT I-GENE
- I-GENE
6 I-GENE
. O

DNA I-GENE
binding I-GENE
assays O
confirmed O
the O
interference O
of O
p30 _RARE_
( O
II I-GENE
) O
with O
the O
assembly O
of O
CREB I-GENE
- I-GENE
Tax I-GENE
- I-GENE
p300 I-GENE
/ I-GENE
CBP I-GENE
multiprotein _RARE_
complexes I-GENE
on O
21 O
- I-GENE
bp O
repeat I-GENE
oligonucleotides O
in O
vitro O
. O

Transient O
transfections O
showed O
that O
a O
single O
mutation I-GENE
( O
556M _RARE_
) O
decreased O
TBLV _RARE_
enhancer I-GENE
activity O
at O
least O
20 O
- I-GENE
fold O
in O
two O
different O
T I-GENE
- I-GENE
cell O
lines O
. O

In O
conclusion O
, O
tube O
size O
estimated O
by O
Cole _RARE_
' O
s O
formula O
tends _RARE_
to O
be O
smaller O
than O
practically _RARE_
appropriate O
tube O
size O
for O
pediatric O
cardiac I-GENE
anesthesia O
, O
and O
therefore O
we O
suggest O
new O
formula O
to O
estimate O
the O
tube O
size O
. O

Thus O
, O
in O
T47D _RARE_
breast O
carcinoma O
cells O
, O
IL I-GENE
- I-GENE
6 I-GENE
acts O
in O
synergy _RARE_
with O
EGF I-GENE
receptor I-GENE
autocrine O
activity O
to O
signal I-GENE
through O
the O
MAPK I-GENE
/ I-GENE
PI3K _RARE_
pathways O
. O

Nerve _RARE_
growth I-GENE
factor I-GENE
( O
NGF _RARE_
) O
and O
retinoic I-GENE
acid I-GENE
( O
RA O
) O
exert O
important O
actions O
on O
PC12 O
cells O
. O

HexA71 _RARE_
negatively O
affects O
RpoS _RARE_
, O
as O
the O
levels O
of O
this O
alternative O
sigma I-GENE
factor I-GENE
are O
higher O
in O
the O
HexA _RARE_
- I-GENE
mutant I-GENE
than O
in O
the O
HexA _RARE_
+ I-GENE
strain O
. O

Moreover O
, O
elderly O
men O
with O
bioavailable _RARE_
estradiol O
levels O
below O
the O
median O
[ O
40 I-GENE
pmol _RARE_
/ I-GENE
liter O
( O
11 I-GENE
pg O
/ I-GENE
ml O
)] O
had O
significantly O
higher O
rates O
of O
bone O
loss O
and O
levels O
of O
bone O
resorption O
markers O
than O
men O
with O
bioavailable _RARE_
estradiol O
levels O
above O
40 I-GENE
pmol _RARE_
/ I-GENE
liter O
. O

The O
histamine O
H1 I-GENE
receptor I-GENE
antagonists O
( O
antihistamines _RARE_
) O
are O
an O
important O
class I-GENE
of O
medications _RARE_
used O
for O
the O
relief _RARE_
of O
common O
symptoms O
associated I-GENE
with O
hyperhistaminic _RARE_
conditions O
occurring O
in O
children O
and O
adults O
. O

The O
production O
of O
ceramide _RARE_
is O
emerging _RARE_
as O
a O
fixture _RARE_
of O
programmed O
cell O
death O
. O

The O
flux _RARE_
rates O
of O
p O
- I-GENE
toluidine _RARE_
decreased O
as O
the O
pH O
value O
in O
the O
donor O
solution O
increased O
. O

Managing _RARE_
HIV I-GENE
. O

BACKGROUND O
: O
There O
is O
increasing O
interest O
on O
the O
part O
of O
investigators _RARE_
and O
the O
public _RARE_
at O
large O
in O
finding O
ways O
to O
study O
and O
improve O
treatments O
for O
the O
seriously _RARE_
mentally _RARE_
ill _RARE_
without O
exposing _RARE_
such O
individuals O
to O
unnecessary _RARE_
risks _RARE_
. O

Multidrug _RARE_
resistance O
in O
Saccharomyces I-GENE
cerevisiae I-GENE
mainly O
results O
from O
the O
overexpression O
of O
genes I-GENE
coding O
for O
the O
membrane I-GENE
efflux _RARE_
pumps _RARE_
, O
the O
major I-GENE
facilitators _RARE_
and O
the O
ABC _RARE_
binding I-GENE
cassette _RARE_
transporters I-GENE
, O
under O
the O
control O
of O
key O
transcription I-GENE
regulators O
encoded I-GENE
by O
the O
PDR1 _RARE_
and O
PDR3 _RARE_
genes I-GENE
. O

Serum I-GENE
PTH I-GENE
tended O
to O
increase O
in O
the O
WL _RARE_
group O
but O
not O
in O
the O
WM _RARE_
group O
( O
P I-GENE
< O
0 O
. O
06 O
). O

Bandshift _RARE_
experiments O
demonstrate O
that O
BmHR3A _RARE_
binds O
specifically O
to O
RORE _RARE_
( O
Retinoic _RARE_
acid I-GENE
- I-GENE
related I-GENE
Orphan _RARE_
receptor I-GENE
Response O
Element _RARE_
)- I-GENE
like I-GENE
sequences I-GENE
in O
the O
promoters I-GENE
of O
both O
genes I-GENE
, O
thus O
suggesting O
a O
direct O
role O
for O
BmHR3A _RARE_
in O
regulating O
the O
expression O
of O
BmGATAbeta _RARE_
and O
ESP _RARE_
genes I-GENE
during O
vitellogenesis _RARE_
. O

Efficacy _RARE_
of O
first O
- I-GENE
generation O
Cavermap _RARE_
to O
verify _RARE_
location O
and O
function O
of O
cavernous _RARE_
nerves O
during O
radical O
prostatectomy _RARE_
: O
a O
multi O
- I-GENE
institutional _RARE_
evaluation O
by O
experienced O
surgeons _RARE_
. O

During O
most O
of O
the O
cell O
cycle O
, O
separase _RARE_
is O
kept O
inactive O
by O
binding I-GENE
to O
an O
inhibitory _RARE_
protein I-GENE
called O
securin _RARE_
. O

In O
conclusion O
, O
obesity O
, O
alcohol O
intake O
, O
and O
multimetabolic _RARE_
disorders O
were O
determined O
to O
be O
independent O
predictors O
for O
the O
development O
of O
hyperuricemia _RARE_
. O

This O
study O
examined O
the O
role O
of O
cholesteryl _RARE_
ester O
transfer I-GENE
( O
CET _RARE_
), O
cholesteryl _RARE_
ester O
transfer I-GENE
protein I-GENE
( O
CETP _RARE_
) O
activity O
, O
and O
phospholipid _RARE_
transfer I-GENE
protein I-GENE
( O
PLTP _RARE_
) O
activity O
in O
the O
increased O
prevalence O
of O
coronary O
artery O
calcification _RARE_
( O
CAC _RARE_
) O
in O
diabetic O
subjects O
compared O
with O
nondiabetic _RARE_
subjects O
and O
in O
the O
loss O
of O
the O
sex _RARE_
difference O
in O
CAC _RARE_
in O
diabetes O
. O

In O
the O
mouse I-GENE
, O
both O
genes I-GENE
reside O
in O
the O
syntenic _RARE_
region I-GENE
8E1 _RARE_
on O
chromosome O
8 I-GENE
. O

We O
observed O
NP _RARE_
/ I-GENE
NMP4 _RARE_
/ I-GENE
CIZ _RARE_
expression O
in O
osteocytes _RARE_
, O
osteoblasts _RARE_
, O
and O
chondrocytes _RARE_
in O
rat I-GENE
bone O
. O

Following O
baseline O
clinical O
examination O
and O
initial O
periodontal O
therapy O
, O
32 O
patients O
received O
mucogingival _RARE_
surgery O
with O
free O
gingival _RARE_
grafts O
for O
treatment O
of O
insufficient O
attached O
gingiva _RARE_
. O

In O
contrast O
, O
the O
failure O
of O
the O
QKTT _RARE_
motif I-GENE
and O
TGN46 _RARE_
cytoplasmic I-GENE
tail O
to O
induce O
steady O
- I-GENE
state O
ER I-GENE
localization O
of O
vesicular O
stomatitis _RARE_
virus I-GENE
glycoprotein I-GENE
( O
VSVG _RARE_
) O
chimeras _RARE_
in O
HeLa O
and O
NRK _RARE_
cells O
indicates O
that O
significant O
differences O
in O
early I-GENE
secretory _RARE_
trafficking O
also O
exist O
. O

We O
previously O
showed O
that O
this O
proteolysis O
1 I-GENE
) O
can O
be O
acutely _RARE_
promoted O
by O
the O
phorbol O
ester O
phorbol O
12 O
- I-GENE
myristate O
13 O
- I-GENE
acetate O
( O
PMA O
), O
2 I-GENE
) O
requires O
a O
metalloprotease _RARE_
activity O
, O
3 I-GENE
) O
generates O
both O
shed _RARE_
GHBP _RARE_
and O
a O
membrane I-GENE
- I-GENE
associated I-GENE
GHR _RARE_
transmembrane I-GENE
/ I-GENE
cytoplasmic I-GENE
domain I-GENE
remnant _RARE_
, O
and O
4 I-GENE
) O
results O
in O
down O
- I-GENE
regulation O
of O
GHR _RARE_
abundance O
and O
GH I-GENE
signaling O
. O

Our O
data O
indicate O
that O
SIP1 _RARE_
is O
required O
to O
confine _RARE_
XBra _RARE_
gene I-GENE
expression O
to O
the O
mesoderm O
. O

Changes O
of O
the O
DB _RARE_
sequence I-GENE
without O
affecting O
the O
postulated O
stem O
structure O
led O
to O
drastic _RARE_
losses _RARE_
of O
translation I-GENE
efficiency O
. O

This O
subfamily I-GENE
of O
genes I-GENE
all O
have O
a O
single O
ATP I-GENE
- I-GENE
binding I-GENE
domain I-GENE
at O
the O
N I-GENE
- I-GENE
terminus O
and O
a O
single O
C I-GENE
- I-GENE
terminal I-GENE
set O
of O
transmembrane I-GENE
segments O
. O

Subsequently _RARE_
, O
these O
coordinates _RARE_
must O
be O
interpreted O
to O
define O
particular O
tissues O
and O
organs O
. O

The O
cyclins _RARE_
bind O
to O
and O
activate O
the O
CDK I-GENE
, O
which O
leads O
to O
phosphorylation O
( O
and O
then O
inhibition O
) O
of O
the O
tumor I-GENE
suppressor I-GENE
protein I-GENE
, O
pRb I-GENE
. O
pRb I-GENE
controls O
commitment _RARE_
to O
progress O
from O
the O
G1 I-GENE
to O
S I-GENE
phase O
, O
at O
least O
in O
part O
by O
repressing O
the O
activity O
of O
the O
E2F I-GENE
transcription I-GENE
factors I-GENE
known O
to O
promote O
cell O
proliferation O
. O

The O
mean O
serum I-GENE
creatinine O
level O
did O
not O
change O
during O
the O
first O
6 I-GENE
months O
after O
withdrawal O
of O
MMF _RARE_
. O

The O
severity O
of O
pathologic O
changes O
increased O
with O
the O
magnitude O
of O
percussion _RARE_
. O

Patients O
with O
antibody I-GENE
peaks O
, O
defined O
as O
fivefold _RARE_
or O
higher O
increase O
in O
antibody I-GENE
titer O
compared O
to O
the O
lowest O
antibody I-GENE
titer O
over O
the O
course O
of O
GBS _RARE_
, O
had O
higher O
disability _RARE_
scores O
during O
the O
first O
two O
weeks O
of O
GBS _RARE_
and O
a O
worse _RARE_
clinical O
outcome O
( O
anti I-GENE
- I-GENE
GM1 _RARE_
IgG I-GENE
and O
anti I-GENE
- I-GENE
GD1a _RARE_
IgM I-GENE
antibody I-GENE
peaks O
) O
and O
axonal _RARE_
damage O
( O
anti I-GENE
- I-GENE
GD1a _RARE_
IgM I-GENE
antibody I-GENE
peaks O
), O
compared O
to O
patients O
without O
peak O
antibody I-GENE
titers _RARE_
. O

At O
20 O
days O
( O
D I-GENE
) O
and O
at O
3 I-GENE
months O
post O
- I-GENE
TBI _RARE_
, O
irradiated O
rats O
had O
a O
significantly O
lower O
percentage O
of O
avoidance _RARE_
than O
controls O
but O
no O
statistical O
difference O
was O
found O
at O
5 I-GENE
months O
post O
- I-GENE
TBI _RARE_
. O
b I-GENE
/ I-GENE
Two O
- I-GENE
way O
avoidance _RARE_
test O
: O
this O
test O
was O
performed O
only O
after O
TBI _RARE_
. O

TE _RARE_
- I-GENE
671 _RARE_
cells O
that O
were O
transfected O
with O
cAMP I-GENE
response I-GENE
element I-GENE
mutant I-GENE
constructs I-GENE
demonstrated O
a O
diminished O
basal O
activity O
of O
the O
GnRH I-GENE
- I-GENE
II I-GENE
promoter I-GENE
. O

The O
severity O
of O
clinical O
course O
was O
expressed O
by O
means O
of O
SOFA _RARE_
score O
( O
group O
A I-GENE
0 O
. O
3 I-GENE
- I-GENE
1 I-GENE
- I-GENE
1 I-GENE
. O
3 I-GENE
point O
, O
group O
B I-GENE
2 I-GENE
. O
2 I-GENE
- I-GENE
2 I-GENE
. O
9 O
- I-GENE
2 I-GENE
. O
6 I-GENE
point O
, O
group O
C I-GENE
7 O
. O
4 I-GENE
- I-GENE
8 I-GENE
. O
3 I-GENE
- I-GENE
7 O
. O
7 O
point O
) O
and O
APACHE _RARE_
II I-GENE
score O
( O
group O
A I-GENE
3 I-GENE
. O
7 O
- I-GENE
7 O
. O
6 I-GENE
- I-GENE
8 I-GENE
. O
1 I-GENE
point O
, O
group O
B I-GENE
8 I-GENE
. O
6 I-GENE
- I-GENE
11 I-GENE
. O
1 I-GENE
- I-GENE
10 O
. O
5 I-GENE
point O
, O
group O
C I-GENE
16 O
. O
3 I-GENE
- I-GENE
15 O
. O
2 I-GENE
- I-GENE
14 O
. O
3 I-GENE
point O
). O

A I-GENE
novel O
potential O
effector O
of O
M I-GENE
- I-GENE
Ras I-GENE
and O
p21 I-GENE
Ras I-GENE
negatively O
regulates O
p21 I-GENE
Ras I-GENE
- I-GENE
mediated O
gene I-GENE
induction O
and O
cell O
growth I-GENE
. O

Promoter O
transcriptional O
activity O
was O
determined O
for O
a O
wide O
5 I-GENE
' O
portion O
of O
the O
human I-GENE
annexin _RARE_
A5 _RARE_
gene I-GENE
, O
from O
bp O
- I-GENE
1275 _RARE_
to O
+ I-GENE
79 O
relative O
to O
the O
most O
5 I-GENE
' O
of O
several O
discrete O
transcription I-GENE
start O
points O
. O

Structure O
of O
the O
EMAPII _RARE_
domain I-GENE
of O
human I-GENE
aminoacyl _RARE_
- I-GENE
tRNA I-GENE
synthetase I-GENE
complex I-GENE
reveals O
evolutionary O
dimer O
mimicry _RARE_
. O

Adding _RARE_
10 O
mmol O
SDS O
/ I-GENE
l O
led O
to O
transient O
inhibition O
of O
acidification O
, O
metal O
solubilization _RARE_
and O
sulfur O
oxidation O
. O

Competition O
electrophoretic O
mobility I-GENE
shift O
and O
immunoshift _RARE_
assays O
confirmed O
that O
NF1 I-GENE
factors I-GENE
present O
in O
nuclear I-GENE
extracts O
of O
HeLa O
and O
CV _RARE_
- I-GENE
1 I-GENE
cells O
bind O
to O
the O
BKV _RARE_
- I-GENE
MLP _RARE_
. O

Northern O
and O
Western O
blot O
analyses O
demonstrated O
that O
Graf2 _RARE_
is O
expressed O
in O
several O
tissues O
, O
with O
the O
highest O
expression O
in O
skeletal I-GENE
muscle I-GENE
. O

A I-GENE
minimal I-GENE
ER3 _RARE_
sequence I-GENE
of O
DNA I-GENE
was O
further O
demonstrated O
to O
function O
as O
a O
FXR _RARE_
HRE _RARE_
and O
was O
bound O
in O
vitro O
by O
FXR _RARE_
- I-GENE
expressing O
yeast I-GENE
extracts O
. O

In O
Ka13 _RARE_
cells O
, O
CoCl _RARE_
( O
2 I-GENE
) O
stimulated O
expression O
of O
a O
luciferase I-GENE
reporter I-GENE
gene I-GENE
under O
the O
control O
of O
a O
15 O
- I-GENE
kilobase O
pair O
mouse I-GENE
ho _RARE_
- I-GENE
1 I-GENE
promoter I-GENE
( O
pHO15luc _RARE_
). O

Nine _RARE_
strains O
were O
subtyped _RARE_
as O
Camp _RARE_
. O
jejuni _RARE_
subsp _RARE_
. O
jejuni _RARE_
biotype _RARE_
II I-GENE
and O
the O
remaining O
ones O
as O
biotype _RARE_
I I-GENE
. O

The O
Ig I-GENE
- I-GENE
related I-GENE
, O
typical O
metazoan _RARE_
, O
module _RARE_
is O
classified O
to O
the O
disulphide _RARE_
lacking O
Ig I-GENE
members I-GENE
and O
represents O
the O
phylogenetic O
earliest _RARE_
member O
of O
this O
group O
. O

In O
budding _RARE_
yeast I-GENE
, O
this O
latter O
checkpoint _RARE_
response I-GENE
involves O
the O
proteins I-GENE
Mad1 _RARE_
, O
2 I-GENE
, O
3 I-GENE
, O
Bub1 _RARE_
and O
Bub3 _RARE_
, O
whose O
vertebrate _RARE_
counterparts O
localize O
to O
unattached _RARE_
kinetochores _RARE_
. O

We O
investigated O
the O
production O
of O
hyaluronan _RARE_
( O
HA I-GENE
) O
and O
its O
effect O
on O
cell O
motility O
in O
cells O
expressing O
the O
v I-GENE
- I-GENE
src I-GENE
mutants I-GENE
. O

Oral _RARE_
supplementation O
of O
L I-GENE
- I-GENE
arginine _RARE_
significantly O
increased O
plasma I-GENE
L I-GENE
- I-GENE
citrulline _RARE_
, O
which O
indicated O
enhancement O
of O
NO O
production O
. O

We O
can O
classify _RARE_
antibiotics O
into O
two O
groups O
based O
on O
initial O
bactericidal O
activity O
against O
P I-GENE
. O
aeruginosa _RARE_
; O
one O
class I-GENE
is O
antibiotics O
having O
rapid O
initial O
killing _RARE_
such O
as O
AMK _RARE_
, O
IPM _RARE_
and O
PAPM _RARE_
, O
the O
other O
is O
CAZ _RARE_
, O
MEPM _RARE_
showing O
slow O
initial O
killing _RARE_
. O

The O
presence O
of O
truncated I-GENE
receptor I-GENE
isoforms I-GENE
in O
diverse O
species O
suggests O
that O
these O
proteins I-GENE
may O
have O
important O
functional O
roles O
in O
regulating O
EGFR I-GENE
activity O
. O

Of O
its O
gene I-GENE
products I-GENE
, O
E6 I-GENE
binds O
to O
and O
inactivates _RARE_
p53 I-GENE
tumor I-GENE
suppressor I-GENE
protein I-GENE
by O
ubiquitin I-GENE
/ I-GENE
proteasome I-GENE
- I-GENE
dependent I-GENE
degradation O
. O

Low O
affinity O
binding I-GENE
of O
Rab6A _RARE_
- I-GENE
GTP I-GENE
was O
also O
observed O
( O
K I-GENE
( O
d O
) O
= O
16 O
microm O
), O
whereas O
Rab1B _RARE_
, O
- I-GENE
5 I-GENE
, O
- I-GENE
7 O
, O
- I-GENE
8 I-GENE
, O
or O
- I-GENE
11A _RARE_
did O
not O
bind O
. O

( O
1997 O
) O
Nature _RARE_
387 _RARE_
, O
370 _RARE_
- I-GENE
376 _RARE_
)], _RARE_
we O
suggest O
that O
the O
metal O
fluoride O
ions O
replaced O
phosphate I-GENE
at O
the O
two O
ATP I-GENE
- I-GENE
binding I-GENE
sites I-GENE
of O
the O
iron O
protein I-GENE
, O
Kp2 _RARE_
. O

A I-GENE
1 I-GENE
- I-GENE
base O
pair O
mismatch _RARE_
within O
the O
corresponding O
region I-GENE
of O
the O
CYP3A4 _RARE_
gene I-GENE
was O
sufficient O
for O
a O
differential O
enhancer I-GENE
activity O
. O

AIMS _RARE_
: O
To O
establish O
a O
baseline O
and O
intraindividual _RARE_
fluctuations O
of O
the O
tumour _RARE_
markers O
CEA _RARE_
, O
CA I-GENE
50 O
and O
CA I-GENE
242 _RARE_
in O
patients O
cured _RARE_
from O
colorectal _RARE_
cancer O
, O
and O
to O
test O
the O
hypothesis O
that O
serum I-GENE
concentrations O
and O
intraindividual _RARE_
fluctuations O
do O
not O
differ O
from O
the O
concentrations O
in O
cancer O
- I-GENE
free O
individuals O
. O

Substitution O
of O
serine I-GENE
residues O
at O
the O
C I-GENE
- I-GENE
terminus O
indicated O
that O
loss O
of O
phosphorylation O
sites I-GENE
did O
not O
appear O
to O
have O
any O
effect O
on O
transcription I-GENE
and O
replication O
. O

Molecular O
analysis O
of O
the O
pRA2 _RARE_
partitioning _RARE_
region I-GENE
: O
ParB _RARE_
autoregulates _RARE_
parAB _RARE_
transcription I-GENE
and O
forms O
a O
nucleoprotein _RARE_
complex I-GENE
with O
the O
plasmid O
partition _RARE_
site I-GENE
, O
parS _RARE_
. O

Tumor I-GENE
cell O
lines O
transduced _RARE_
at O
an O
MOI _RARE_
of O
8 I-GENE
for O
3 I-GENE
days O
led O
to O
> O
90 O
% O
gene I-GENE
transfer I-GENE
efficiency O
. O

No O
ISREs _RARE_
could O
be O
identified O
in O
the O
mouse I-GENE
promoter I-GENE
. O

GABA _RARE_
( O
B I-GENE
) O
R1g _RARE_
was O
expressed O
in O
both O
brain O
and O
peripheral O
tissues O
. O

Granulocyte _RARE_
colony I-GENE
- I-GENE
stimulating I-GENE
factor I-GENE
( O
G I-GENE
- I-GENE
CSF I-GENE
) O
administration O
in O
vivo O
has O
been O
shown O
to O
improve O
the O
defence _RARE_
mechanisms O
against O
infection O
by O
different O
microbes _RARE_
. O

Use O
of O
a O
dual O
- I-GENE
pulse O
lithotripter _RARE_
to O
generate O
a O
localized O
and O
intensified _RARE_
cavitation _RARE_
field O
. O

The O
best O
regression O
model O
for O
predicting O
changes O
in O
the O
WCXR _RARE_
included O
time O
to O
first O
positive O
culture O
and O
antibody I-GENE
titer O
for O
Pa _RARE_
elastase I-GENE
. O

RESULTS O
: O
The O
parameters O
SF2 _RARE_
and O
plating _RARE_
efficiency O
were O
stable O
throughout O
the O
4 I-GENE
- I-GENE
year O
test O
period O
. O

The O
process O
has O
been O
applied O
to O
the O
river _RARE_
reclamation _RARE_
in O
Yangpu _RARE_
District _RARE_
of O
Shanghai _RARE_
City O
, O
China _RARE_
. O

Multiple O
regression O
analysis O
performed O
between O
these O
long O
- I-GENE
term O
abiotic _RARE_
factors I-GENE
and O
nymphal _RARE_
abundance O
in O
positive O
sites I-GENE
showed O
high O
relationship O
( O
R2 _RARE_
coefficients O
) O
for O
every O
habitat _RARE_
category O
and O
explained O
> O
50 O
% O
of O
the O
variation O
in O
tick _RARE_
abundance O
. O

The O
v I-GENE
- I-GENE
Src I-GENE
SH3 I-GENE
domain I-GENE
facilitates _RARE_
a O
cell O
adhesion I-GENE
- I-GENE
independent O
association O
with O
focal _RARE_
adhesion I-GENE
kinase I-GENE
. O

Of O
the O
six O
cases O
of O
malignant O
polyposis _RARE_
, O
none O
were O
identified O
using O
CT _RARE_
, O
and O
only O
two O
were O
diagnosed O
by O
small I-GENE
bowel O
follow O
- I-GENE
through O
. O

Right _RARE_
LHR I-GENE
( O
R I-GENE
- I-GENE
LHR I-GENE
) O
provided O
the O
best O
interobserver _RARE_
and O
intraobserver _RARE_
reproducibility O
. O

We O
also O
reported O
the O
identification O
of O
three O
corresponding O
alternative O
first O
exons O
and O
an O
intronic _RARE_
promoter I-GENE
in O
the O
human I-GENE
PDE5A _RARE_
gene I-GENE
. O

Of O
major I-GENE
concern _RARE_
to O
food O
processors _RARE_
is O
the O
inadvertent _RARE_
cross O
- I-GENE
contact O
of O
food O
products I-GENE
with O
allergenic _RARE_
residues O
, O
which O
could O
result O
in O
potentially O
life O
- I-GENE
threatening _RARE_
reactions O
in O
those O
with O
a O
food O
allergy O
. O

Diffuse _RARE_
myalgias _RARE_
were O
more O
frequent O
in O
patients O
with O
than O
without O
an O
MMF _RARE_
lesion O
at O
deltoid _RARE_
muscle I-GENE
biopsy O
( O
P I-GENE
< O
0 O
. O
0001 O
). O

Functional O
analysis O
of O
various O
PTP I-GENE
- I-GENE
deficient O
DT40 _RARE_
B I-GENE
cell O
lines O
stably O
expressing O
wild I-GENE
- I-GENE
type I-GENE
chimeric I-GENE
Fc I-GENE
gamma I-GENE
RIIB1 _RARE_
- I-GENE
PECAM _RARE_
- I-GENE
1 I-GENE
receptor I-GENE
indicated O
that O
cytoplasmic I-GENE
Src I-GENE
homology I-GENE
2 I-GENE
- I-GENE
domain I-GENE
- I-GENE
containing O
phosphatases I-GENE
, O
SHP I-GENE
- I-GENE
1 I-GENE
and O
SHP I-GENE
- I-GENE
2 I-GENE
, O
were O
both O
necessary O
and O
sufficient O
to O
deliver _RARE_
inhibitory _RARE_
negative O
regulation O
upon O
coligation _RARE_
of O
BCR I-GENE
complex I-GENE
with O
inhibitory _RARE_
receptor I-GENE
. O

Subtraction _RARE_
hybridization O
identified O
melanoma O
differentiation O
associated I-GENE
gene I-GENE
- I-GENE
7 O
( O
mda _RARE_
- I-GENE
7 O
), O
as O
a O
gene I-GENE
induced O
during O
these O
physiological O
changes O
in O
human I-GENE
melanoma O
cells O
. O

A I-GENE
rare O
case O
of O
primary O
group O
A I-GENE
streptococcal _RARE_
peritonitis _RARE_
. O

Among O
individuals O
, O
however O
, O
changes O
were O
strongly O
correlated O
with O
ACR _RARE_
levels O
at O
baseline O
. O

RESULTS O
: O
The O
subjects O
in O
the O
augmented O
feedback _RARE_
group O
significantly O
reduced O
their O
peak O
vertical O
ground _RARE_
reaction O
force O
in O
both O
post O
- I-GENE
test O
conditions O
( O
2 I-GENE
- I-GENE
minute O
post O
- I-GENE
test O
reduction O
, O
0 O
. O
85 O
+/- O
0 O
. O
62 O
; O
1 I-GENE
- I-GENE
week O
post O
- I-GENE
test O
reduction O
, O
0 O
. O
74 O
+/- O
0 O
. O
58 O
) O
as O
compared O
to O
the O
sensory O
, O
control O
I I-GENE
, O
and O
control O
II I-GENE
feedback _RARE_
groups O
. O

The O
blood O
levels O
of O
lactate _RARE_
, O
pyruvate _RARE_
and O
amino O
acids O
were O
not O
elevated O
. O

Histological O
examination O
showed O
lichenoid _RARE_
changes O
, O
acantholytic _RARE_
blister _RARE_
formation O
and O
apoptotic O
keratinocytes _RARE_
. O

Enantiomer _RARE_
separation O
of O
venlafaxine _RARE_
and O
O I-GENE
- I-GENE
desmethylvenlafaxine _RARE_
in O
human I-GENE
plasma I-GENE
. O

Paul _RARE_
Monagle _RARE_
addresses _RARE_
the O
epidemiology _RARE_
of O
neonatal O
thrombosis O
outside O
of O
the O
central O
nervous O
system O
in O
both O
arterial O
and O
venous O
locations O
, O
and O
those O
that O
occur O
in O
utero _RARE_
. O

The O
MSL _RARE_
complex I-GENE
is O
specifically O
localized O
on O
the O
male O
X I-GENE
chromosome O
to O
increase O
its O
expression O
approximately O
2 I-GENE
- I-GENE
fold O
. O

Effects O
of O
a O
booster _RARE_
dose O
of O
tetanus _RARE_
toxoid _RARE_
after O
different O
primary O
courses O
of O
vaccination O
: O
implications O
on O
the O
use O
of O
immune I-GENE
globulin I-GENE
. O

Our O
results O
suggest O
that O
the O
C I-GENE
- I-GENE
terminal I-GENE
region I-GENE
of O
Crk I-GENE
contains O
negative O
regulatory I-GENE
elements I-GENE
important O
for O
both O
Abl I-GENE
and O
FAK I-GENE
dependent I-GENE
signal I-GENE
pathways O
, O
and O
offers O
a O
paradigm _RARE_
for O
an O
autoinhibitory _RARE_
region I-GENE
in O
the O
SH3 I-GENE
linker _RARE_
/ I-GENE
C I-GENE
- I-GENE
terminal I-GENE
SH3 I-GENE
domain I-GENE
. O

The O
distribution O
of O
red _RARE_
rice _RARE_
cultivation _RARE_
in O
Sri _RARE_
Lanka _RARE_
is O
coincident _RARE_
with O
the O
HIDD _RARE_
villages _RARE_
. O

Prophylactic _RARE_
lymph O
node O
dissection O
or O
radiation O
therapy O
to O
the O
nodal O
chain I-GENE
may O
decrease O
local O
recurrence O
but O
does O
not O
consistently O
affect O
overall O
survival O
. O

Secretion _RARE_
of O
interleukin I-GENE
- I-GENE
8 I-GENE
, O
RANTES _RARE_
, O
macrophage I-GENE
inflammatory O
protein I-GENE
1alpha I-GENE
, O
and O
10 O
- I-GENE
kappaDa _RARE_
IFN I-GENE
- I-GENE
gamma I-GENE
- I-GENE
inducible I-GENE
protein I-GENE
were O
increased O
in O
differentiating O
keratinocytes _RARE_
by O
E6 I-GENE
. O

CONCLUSIONS O
: O
ChromaFlo _RARE_
- I-GENE
enhanced O
IVUS _RARE_
demonstrates O
colorized _RARE_
blood O
flow O
inside _RARE_
the O
vessel O
lumen _RARE_
, O
which O
is O
helpful O
in O
distinguishing _RARE_
echolucent _RARE_
disease O
from O
luminal O
blood O
flow O
and O
can O
also O
be O
used O
to O
perform O
peripheral O
interventions _RARE_
in O
patients O
with O
renal O
failure O
or O
allergy O
, O
avoiding _RARE_
the O
use O
of O
contrast O
media O
. O

Additional _RARE_
factors I-GENE
such O
as O
advanced O
age O
, O
concomitant O
use O
of O
corticosteroids O
or O
anticoagulants _RARE_
, O
prior O
ulcer O
complications O
and O
co O
- I-GENE
morbid _RARE_
diseases O
may O
further O
increase O
the O
risk O
of O
bleeding O
. O

CONCLUSIONS O
: O
Using O
icodextrin _RARE_
- I-GENE
based O
instead O
of O
glucose I-GENE
- I-GENE
based O
PD _RARE_
fluids O
can O
largely O
reduce O
the O
formation O
of O
Amadori _RARE_
albumin I-GENE
and O
AGEs _RARE_
. O

A I-GENE
central O
finding O
is O
the O
identification O
of O
a O
GC _RARE_
- I-GENE
rich O
sequence I-GENE
in O
the O
- I-GENE
99 O
/- O
91 O
Cp I-GENE
region I-GENE
that O
is O
essential O
for O
oriPI _RARE_
- I-GENE
EBNA1 _RARE_
- I-GENE
independent O
as O
well O
as O
oriPI _RARE_
- I-GENE
EBNA1 _RARE_
- I-GENE
dependent I-GENE
activity O
of O
the O
promoter I-GENE
. O

Furthermore O
, O
SB203580 _RARE_
inhibited O
LPS _RARE_
- I-GENE
induced O
activation O
of O
Sp1 I-GENE
, O
as O
well O
as O
the O
promoter I-GENE
activity O
in O
cells O
transfected O
with O
a O
plasmid O
containing O
the O
Sp1 I-GENE
consensus I-GENE
sequence I-GENE
. O

A I-GENE
new O
echocardiographic O
technique O
is O
described O
with O
a O
conventional O
M I-GENE
mode O
, O
digitalised _RARE_
2D _RARE_
and O
tissular _RARE_
Doppler O
which O
has O
a O
comparable O
ability O
to O
identify O
the O
anomalous _RARE_
pathways O
of O
electric _RARE_
conduction O
using O
a O
non O
- I-GENE
invasive O
method O
. O

Is O
clopidogrel _RARE_
superior O
to O
aspirin _RARE_
in O
secondary O
prevention O
of O
vascular I-GENE
disease O
? O
The O
cornerstone _RARE_
in O
clinical O
evidence O
of O
the O
relative O
efficacy O
of O
thienopyridines _RARE_
( O
clopidogrel _RARE_
, O
ticlopidine _RARE_
) O
versus O
aspirin _RARE_
in O
the O
secondary O
prevention O
of O
vascular I-GENE
disease O
is O
the O
Clopidogrel _RARE_
versus O
Aspirin _RARE_
in O
Patients O
at O
Risk O
of O
Ischaemic _RARE_
Events _RARE_
trial O
. O

The O
role O
of O
the O
Vp1 _RARE_
DBD _RARE_
during O
infection O
was O
investigated O
by O
taking O
advantage O
of O
NLS O
phenotypic _RARE_
complementation O
( O
N I-GENE
. O

The O
probability _RARE_
of O
treatment O
with O
lamotrigine _RARE_
being O
maintained O
for O
six O
months O
was O
86 _RARE_
%, O
for O
twelve _RARE_
months O
61 O
% O
and O
for O
three O
years O
31 O
%. O

Recent O
advances _RARE_
have O
shown O
that O
volatile O
sulfur O
is O
a O
result O
of O
ecological _RARE_
interactions O
and O
transformation O
processes O
through O
planktonic _RARE_
food O
webs _RARE_
. O

OsBBPI _RARE_
was O
found O
to O
be O
rapidly O
induced O
in O
rice _RARE_
seedling _RARE_
leaf O
in O
response I-GENE
to O
cut I-GENE
, O
exogenous O
jasmonic _RARE_
acid I-GENE
( O
JA _RARE_
), O
and O
two O
potent O
protein I-GENE
phosphatase I-GENE
2A I-GENE
( O
PP2A I-GENE
) O
inhibitors O
, O
cantharidin _RARE_
( O
CN _RARE_
) O
and O
endothall _RARE_
( O
EN _RARE_
), O
in O
a O
light I-GENE
/ I-GENE
dark O
-, _RARE_
time O
- I-GENE
and O
dose O
- I-GENE
dependent I-GENE
manner O
; O
this O
induction O
was O
completely O
inhibited O
by O
cycloheximide _RARE_
( O
CHX _RARE_
), O
indicating O
a O
requirement O
for O
de O
novo _RARE_
protein I-GENE
synthesis O
in O
its O
induction O
. O

Analysis O
of O
ace2Delta _RARE_
cells O
reveals O
that O
Ace2p _RARE_
is O
required O
for O
cell O
separation O
but O
not O
for O
polarized _RARE_
growth I-GENE
. O

The O
purpose O
of O
this O
investigation O
was O
to O
study O
the O
morphological O
characteristics O
of O
the O
fibrous _RARE_
tissue I-GENE
capsule _RARE_
resulting O
from O
the O
implantation O
of O
aluminum O
calcium O
phosphate I-GENE
( O
ALCAP _RARE_
) O
and O
hydroxyapetite _RARE_
( O
HA I-GENE
) O
bioceramics _RARE_
. O

The O
event O
rate O
in O
patients O
with O
chronic O
Irr _RARE_
- I-GENE
rMFP _RARE_
or O
Un _RARE_
- I-GENE
nrMFP _RARE_
was O
markedly O
higher O
than O
it O
was O
in O
those O
with O
Rev I-GENE
- I-GENE
rMFP _RARE_
or O
Sta _RARE_
- I-GENE
nrMFP _RARE_
. O

In O
summary O
, O
we O
conclude O
that O
the O
adenoviral _RARE_
oncoprotein _RARE_
E1A I-GENE
activates O
transcription I-GENE
from O
the O
endogenous I-GENE
AP I-GENE
- I-GENE
2alpha I-GENE
gene I-GENE
, O
an O
effect O
that O
involves O
transcriptional O
derepression O
of O
the O
AP I-GENE
- I-GENE
2alpha I-GENE
promoter I-GENE
by O
interaction O
of O
E1A I-GENE
with O
the O
AP I-GENE
- I-GENE
2rep _RARE_
corepressor _RARE_
CtBP1 _RARE_
. O

Unusual _RARE_
two O
- I-GENE
domain I-GENE
arginine _RARE_
kinases I-GENE
( O
AKs _RARE_
) O
arose _RARE_
independently O
at O
least O
two O
times O
during O
molecular O
evolution O
of O
phosphagen _RARE_
kinases I-GENE
: O
AKs _RARE_
from O
the O
primitive _RARE_
sea O
anemone _RARE_
Anthopleurura _RARE_
japonicus _RARE_
and O
from O
the O
clam _RARE_
Pseudocardium _RARE_
sachalinensis _RARE_
. O

Mutagenesis _RARE_
of O
SNT1 _RARE_
( O
IRS I-GENE
) O
CX _RARE_
identified O
three O
classes O
of O
effector O
motifs I-GENE
within O
SNT _RARE_
critical O
for O
both O
sustained O
ERK I-GENE
activation O
and O
neuronal O
differentiation O
: O
1 I-GENE
) O
four O
phosphotyrosine _RARE_
motifs I-GENE
that O
mediate O
recruitment O
of O
Grb2 I-GENE
, O
2 I-GENE
) O
two O
phosphotyrosine _RARE_
motifs I-GENE
that O
mediate O
recruitment O
of O
Shp2 _RARE_
, O
and O
3 I-GENE
) O
a O
C I-GENE
- I-GENE
terminal I-GENE
motif I-GENE
that O
functions O
by O
helping _RARE_
to O
recruit O
Sos I-GENE
. O

CONCLUSIONS O
: O
Our O
meta _RARE_
- I-GENE
analysis O
of O
randomized O
controlled O
trials O
of O
HRT _RARE_
noted O
a O
statistically O
significant O
reduction O
in O
nonvertebral _RARE_
fractures _RARE_
. O

However O
, O
C4B _RARE_
proteins I-GENE
encoded I-GENE
by O
monomodular _RARE_
short O
genes I-GENE
may O
have O
relatively O
higher O
concentrations O
than O
those O
from O
long O
C4A _RARE_
genes I-GENE
. O

CSR _RARE_
is O
directed O
to O
specific I-GENE
heavy I-GENE
chain I-GENE
isotypes _RARE_
by O
cytokines O
and O
B I-GENE
cell O
activators _RARE_
that O
induce O
transcription I-GENE
from O
the O
unrearranged _RARE_
, O
or O
germline _RARE_
( O
GL _RARE_
), O
C I-GENE
( O
H I-GENE
) O
region I-GENE
genes I-GENE
. O

The O
patterns O
of O
early I-GENE
mRNA I-GENE
and O
protein I-GENE
expression O
in O
these O
seven O
mutants I-GENE
were O
examined O
, O
and O
it O
was O
found O
that O
mutation I-GENE
of O
the O
T I-GENE
'( _RARE_
135 O
) O
acceptor O
site I-GENE
resulted O
in O
the O
utilization O
of O
cryptic _RARE_
splice O
sites I-GENE
and O
the O
generation O
of O
new O
T I-GENE
' O
species O
. O

Mutational O
analysis O
showed O
that O
the O
U O
- I-GENE
box I-GENE
, O
like I-GENE
the O
RING _RARE_
finger I-GENE
in O
other O
proteins I-GENE
, O
forms O
the O
physical O
basis O
for O
the O
interaction O
with O
E2 I-GENE
enzymes O
. O

GafChromic _RARE_
( O
MD _RARE_
- I-GENE
55 O
- I-GENE
2 I-GENE
) O
radiochromic _RARE_
film _RARE_
has O
become O
increasingly _RARE_
popular _RARE_
for O
medical O
applications O
and O
has O
proven O
to O
be O
useful O
for O
brachytherapy _RARE_
dosimetry _RARE_
. O

The O
438 _RARE_
bp O
EcoRI I-GENE
fragment I-GENE
, O
which O
was O
detected O
by O
Southern O
hybridization O
, O
reveals O
an O
open O
reading O
frame O
which O
encodes O
a O
protein I-GENE
of O
103 _RARE_
amino O
acids O
. O

Furthermore O
, O
hormonal O
regulation O
of O
G I-GENE
( O
1 I-GENE
) O
gene I-GENE
transcription I-GENE
can O
occur O
even O
without O
additional O
activation O
of O
the O
Mek _RARE_
- I-GENE
Erk1 _RARE_
/ I-GENE
2 I-GENE
pathway O
by O
estrogen I-GENE
receptors I-GENE
. O

In O
mammalian I-GENE
tissue I-GENE
culture O
cells O
, O
overexpression O
of O
any O
of O
the O
four O
mouse I-GENE
deltex _RARE_
homologs I-GENE
suppressed O
the O
transcriptional O
activity O
of O
E47 _RARE_
, O
a O
basic I-GENE
helix I-GENE
- I-GENE
loop I-GENE
- I-GENE
helix I-GENE
( O
bHLH I-GENE
) O
protein I-GENE
, O
in O
a O
manner O
similar O
to O
suppression O
by O
an O
activated I-GENE
form O
of O
human I-GENE
Notch1 _RARE_
or O
human I-GENE
DTX1 _RARE_
. O

The O
authors O
undertook _RARE_
a O
retrospective O
analysis O
of O
pathology O
with O
quantification _RARE_
of O
the O
percentage O
of O
papillary _RARE_
serous _RARE_
component O
(% _RARE_
PSC _RARE_
) O
and O
p53 I-GENE
expression O
. O

This O
function O
requires O
not O
only O
the O
kinase I-GENE
domain I-GENE
of O
Csk I-GENE
, O
but O
also O
its O
Src I-GENE
homology I-GENE
3 I-GENE
( O
SH3 I-GENE
) O
and O
SH2 I-GENE
regions O
. O

Nucleotide O
sequence I-GENE
, O
transcription I-GENE
map O
, O
and O
mutation I-GENE
analysis O
of O
the O
13q14 _RARE_
chromosomal I-GENE
region I-GENE
deleted O
in O
B I-GENE
- I-GENE
cell O
chronic O
lymphocytic _RARE_
leukemia I-GENE
. O

In O
conclusion O
, O
primary O
chemotherapy O
based O
on O
high O
dose O
MTX _RARE_
and O
ara _RARE_
- I-GENE
C I-GENE
is O
highly O
efficient O
in O
PCNSL _RARE_
. O

NGF _RARE_
, O
but O
not O
EGF I-GENE
, O
enhances O
the O
upper O
bands O
, O
corresponding O
to O
phosphorylated O
Fra _RARE_
- I-GENE
2 I-GENE
. O

METHODS O
AND O
RESULTS O
: O
Palmaz _RARE_
- I-GENE
Schatz _RARE_
stents _RARE_
were O
dip _RARE_
- I-GENE
coated _RARE_
with O
paclitaxel _RARE_
( O
0 O
, O
0 O
. O
2 I-GENE
, O
15 O
, O
or O
187 _RARE_
microgram O
/ I-GENE
stent _RARE_
) O
by O
immersion O
in O
ethanolic _RARE_
paclitaxel _RARE_
and O
evaporation _RARE_
of O
the O
solvent O
. O

Currently _RARE_
, O
the O
clinical O
use O
of O
5 I-GENE
- I-GENE
aminolaevulinic _RARE_
acid I-GENE
( O
ALA _RARE_
) O
induced O
protoporphyrin _RARE_
IX I-GENE
( O
PPIX _RARE_
) O
for O
photodynamic _RARE_
therapy O
( O
PDT _RARE_
) O
is O
limited O
by O
the O
maximum O
tolerated O
oral O
ALA _RARE_
dose O
( O
60 O
mg O
/ I-GENE
kg O
). O

A I-GENE
twelfth _RARE_
insertion O
disrupts _RARE_
two O
genes I-GENE
, O
Nrk _RARE_
, O
a O
" O
neurospecific _RARE_
" O
receptor I-GENE
tyrosine I-GENE
kinase I-GENE
, O
and O
Tpp _RARE_
, O
which O
encodes O
a O
neuropeptidase _RARE_
. O

These O
results O
indicate O
that O
ATF4 _RARE_
regulates O
basal O
and O
CdCl _RARE_
( O
2 I-GENE
)- I-GENE
induced O
expression O
of O
the O
ho _RARE_
- I-GENE
1 I-GENE
gene I-GENE
in O
a O
cell O
- I-GENE
specific I-GENE
manner O
and O
possibly O
in O
a O
complex I-GENE
with O
Nrf2 _RARE_
. O

Adjuvant _RARE_
and O
neoadjuvant _RARE_
treatment O
of O
breast O
cancer O
. O

The O
% O
SVend _RARE_
of O
HCM _RARE_
- I-GENE
I I-GENE
was O
significantly O
lower O
than O
the O
respective O
values O
of O
the O
HCM _RARE_
- I-GENE
II I-GENE
and O
Control O
groups O
. O

Inhibition O
of O
the O
Raf I-GENE
- I-GENE
1 I-GENE
target O
ERK I-GENE
kinase I-GENE
( O
MEK I-GENE
) O
either O
attenuated O
or O
abolished O
Rp _RARE_
- I-GENE
cAMPS _RARE_
- I-GENE
and O
PKI _RARE_
- I-GENE
induced O
ERK I-GENE
activation O
, O
caldesmon _RARE_
phosphorylation O
, O
and O
stress I-GENE
fiber O
formation O
. O

In O
the O
TVD _RARE_
- I-GENE
patients O
decreases O
in O
skin O
blood O
flow O
were O
similar O
compared O
with O
the O
healthy O
controls O
. O

Analysis O
of O
mCTR _RARE_
mRNAs I-GENE
has O
revealed O
that O
the O
three O
alternative O
promoters I-GENE
give O
rise O
to O
at O
least O
seven O
mCTR _RARE_
isoforms I-GENE
in O
the O
5 I-GENE
' O
region I-GENE
of O
the O
gene I-GENE
and O
generate O
5 I-GENE
'- I-GENE
untranslated O
regions O
of O
very O
different O
lengths O
. O

The O
regulation O
of O
PGHS _RARE_
- I-GENE
2 I-GENE
mRNA I-GENE
and O
protein I-GENE
was O
studied O
in O
primary O
cultures O
of O
bovine I-GENE
uterine O
stromal _RARE_
cells O
stimulated O
with O
phorbol O
12 O
- I-GENE
myristate O
13 O
- I-GENE
acetate O
( O
PMA O
; O
100 O
nM O
). O

There O
was O
no O
evidence O
of O
linkage O
disequilibrium _RARE_
between O
the O
polymorphic O
site I-GENE
in O
the O
B I-GENE
cell O
specific I-GENE
promoter I-GENE
and O
those O
in O
the O
3 I-GENE
' O
UTR I-GENE
. O

Several O
dozen _RARE_
HIF I-GENE
- I-GENE
1 I-GENE
targets O
are O
known O
, O
including O
the O
gene I-GENE
encoding O
vascular I-GENE
endothelial I-GENE
growth I-GENE
factor I-GENE
( O
VEGF I-GENE
). O

In O
Klinefelter _RARE_
' O
s O
syndrome O
( O
47XXY _RARE_
), O
serum I-GENE
testosterone O
levels O
are O
at O
the O
lower O
end O
of O
the O
normal O
range O
and O
dihydrotestosterone _RARE_
levels O
are O
low O
. O

The O
protein I-GENE
is O
composed O
of O
two O
major I-GENE
domains I-GENE
separated O
by O
a O
hydrophobic O
linker _RARE_
region I-GENE
of O
20 O
amino O
acid I-GENE
residues O
. O

When O
mixed O
with O
aqueous O
solutions O
of O
TMT _RARE_
- I-GENE
55 O
, O
aqueous O
solutions O
of O
either O
reagent _RARE_
- I-GENE
grade O
zinc I-GENE
, O
cadmium O
, O
or O
lead O
salts _RARE_
precipitate _RARE_
crystalline O
" O
Zn _RARE_
- I-GENE
TMT _RARE_
", _RARE_
amorphous _RARE_
or O
crystalline O
" O
Cd O
- I-GENE
TMT _RARE_
" O
or O
amorphous _RARE_
" O
Pb _RARE_
- I-GENE
TMT _RARE_
" O
( O
M3 _RARE_
[ O
S3C3N3 _RARE_
] O
2 I-GENE
. O
nH2O _RARE_
, O
where O
M I-GENE
= O
Cd2 _RARE_
+, _RARE_
Pb2 _RARE_
+, _RARE_
and O
Zn2 _RARE_
+ I-GENE
and O
n O
> O
or O
= O
0 O
) O
that O
may O
eventually _RARE_
crystallize _RARE_
if O
stored O
in O
air O
. O

Online _RARE_
teaching _RARE_
: O
design O
and O
techniques O
. O

This O
interaction O
is O
reciprocal O
, O
since O
C I-GENE
/ I-GENE
EBP I-GENE
dimer O
binding I-GENE
to O
a O
strong O
C I-GENE
/ I-GENE
EBP I-GENE
site I-GENE
leads O
to O
enhanced O
CREB I-GENE
- I-GENE
1 I-GENE
recruitment O
to O
ATF I-GENE
/ I-GENE
CREB I-GENE
sites I-GENE
that O
are O
weakly O
bound O
by O
CREB I-GENE
. O

The O
absorbed O
dose O
was O
measured O
by O
combination O
of O
two O
integrating _RARE_
detectors _RARE_
: O
thermo _RARE_
- I-GENE
luminescent _RARE_
dosemeter _RARE_
of O
Mg2SiO4 _RARE_
: O
Tb _RARE_
( O
TDMS _RARE_
) O
and O
plastic _RARE_
nuclear I-GENE
track _RARE_
detector O
( O
PNTD _RARE_
). O

To O
determine O
the O
genomic O
complexity O
of O
the O
deleted O
region I-GENE
shared O
among O
tumors O
, O
we O
assembled O
a O
physical O
map O
of O
the O
I I-GENE
Mbp _RARE_
SRO _RARE_
consisting O
predominantly O
of O
bacteriophage _RARE_
P1 I-GENE
- I-GENE
derived I-GENE
artificial O
chromosome O
( O
PAC _RARE_
) O
clones O
. O

Thus O
, O
Xlim _RARE_
- I-GENE
1 I-GENE
not O
only O
contains O
a O
unique O
tyrosine I-GENE
- I-GENE
rich O
activation O
domain I-GENE
but O
also O
contains O
a O
negative O
regulatory I-GENE
domain I-GENE
in O
CT239 _RARE_
- I-GENE
403 _RARE_
, O
suggesting O
a O
complex I-GENE
regulatory I-GENE
mechanism O
underlying O
the O
transcriptional O
activity O
of O
Xlim _RARE_
- I-GENE
1 I-GENE
in O
the O
organizer _RARE_
. O

Low O
- I-GENE
selenium O
diet O
has O
a O
human I-GENE
unfavourable _RARE_
impact O
. O

In O
the O
next O
week O
, O
the O
beta I-GENE
- I-GENE
adrenergic I-GENE
antagonist O
atenolol _RARE_
was O
added O
at O
an O
initial O
dose O
of O
25 O
mg O
/ I-GENE
day O
and O
titrated _RARE_
to O
50 O
mg O
/ I-GENE
day O
within O
1 I-GENE
week O
. O

To O
assess O
more O
specific I-GENE
PKA I-GENE
- I-GENE
dependent I-GENE
mediation _RARE_
of O
LH I-GENE
' O
s O
contribution O
to O
combined O
hormonal O
drive O
, O
the O
LDL I-GENE
receptor I-GENE
(- O
1076 _RARE_
to O
+ I-GENE
11 I-GENE
bp O
) O
reporter I-GENE
plasmid O
was O
cotransfected O
with O
a O
full I-GENE
- I-GENE
sequence I-GENE
rabbit _RARE_
muscle I-GENE
protein I-GENE
kinase I-GENE
inhibitor I-GENE
( O
PKI _RARE_
) O
minigene _RARE_
driven O
constitutively O
by O
a O
Rous _RARE_
sarcoma I-GENE
virus I-GENE
promoter I-GENE
. O

In O
SN _RARE_
- I-GENE
48 O
neuronal O
cells O
that O
express O
MR O
, O
GR I-GENE
, O
and O
5 I-GENE
- I-GENE
HT1A _RARE_
receptors I-GENE
, O
deletion I-GENE
or O
inactivation O
of O
the O
nGRE _RARE_
( O
negative O
GRE _RARE_
) O
eliminated _RARE_
negative O
regulation O
of O
the O
rat I-GENE
5 I-GENE
- I-GENE
HT1A _RARE_
or O
heterologous O
promoters I-GENE
by O
corticosteroids O
, O
whereas O
its O
inclusion O
conferred O
corticosteroid _RARE_
- I-GENE
induced O
inhibition O
to O
a O
heterologous O
promoter I-GENE
. O

Transition _RARE_
between O
P I-GENE
- I-GENE
and O
H I-GENE
- I-GENE
BPPV _RARE_
was O
found O
in O
6 I-GENE
cases O
. O

These O
included O
HNF I-GENE
- I-GENE
3 I-GENE
beta I-GENE
, O
HFH _RARE_
- I-GENE
1 I-GENE
, O
HFH _RARE_
- I-GENE
2 I-GENE
, O
HFH _RARE_
- I-GENE
3 I-GENE
, O
C I-GENE
/ I-GENE
EBP I-GENE
, O
and O
C I-GENE
/ I-GENE
EBP I-GENE
beta I-GENE
, O
all O
of O
which O
are O
consistent O
with O
the O
tissue I-GENE
- I-GENE
specific I-GENE
expression O
profiles O
of O
the O
gene I-GENE
. O

RESULTS O
: O
Of O
the O
24 O
patients O
, O
6 I-GENE
had O
Grade _RARE_
1 I-GENE
pneumonitis _RARE_
, O
and O
13 O
had O
Grade _RARE_
2 I-GENE
pneumonitis _RARE_
. O

METHODS O
: O
The O
passive O
and O
active O
transport O
of O
fluorescein _RARE_
through O
the O
BRB _RARE_
was O
quantitated _RARE_
by O
vitreous O
fluorometry _RARE_
. O

Sixteen _RARE_
out O
of O
52 O
seropositive O
MS O
patients O
( O
30 O
. O
8 I-GENE
%) O
showed O
intrathecal _RARE_
synthesis O
of O
C I-GENE
. O
pneumoniae _RARE_
- I-GENE
specific I-GENE
IgG I-GENE
but O
only O
one O
of O
43 _RARE_
seropositive O
controls O
( O
2 I-GENE
. O
3 I-GENE
%). O

Consistent O
with O
the O
specificity O
observed O
for O
the O
interaction O
of O
DmCKIIalpha _RARE_
with O
these O
bHLH I-GENE
proteins I-GENE
, O
sequence I-GENE
alignment O
suggests O
that O
only O
m5 _RARE_
, O
m7 _RARE_
, O
and O
m8 _RARE_
contain O
a O
consensus I-GENE
site I-GENE
for O
phosphorylation O
by O
CKII _RARE_
within O
a O
subdomain _RARE_
unique O
to O
these O
three O
proteins I-GENE
. O

Deletion O
of O
the O
potential O
initiator O
element I-GENE
does O
not O
affect O
repression O
of O
the O
p21 I-GENE
promoter I-GENE
by O
c I-GENE
- I-GENE
Myc I-GENE
. O

PATIENTS O
AND O
METHODS O
: O
Between _RARE_
June _RARE_
1991 O
and O
December _RARE_
1996 O
, O
we O
administered O
the O
nucleoside _RARE_
analog O
2 I-GENE
- I-GENE
chlorodeoxyadenosine _RARE_
( O
2 I-GENE
- I-GENE
CDA _RARE_
) O
to O
73 O
children O
with O
primary O
AML _RARE_
and O
20 O
children O
with O
secondary O
AML _RARE_
or O
myelodysplastic _RARE_
syndrome O
( O
MDS _RARE_
). O

Drosophila I-GENE
Menin1 _RARE_
gene I-GENE
transcripts I-GENE
use O
alternative O
polyadenylation O
sites I-GENE
resulting O
in O
4 I-GENE
. O
3 I-GENE
and O
5 I-GENE
- I-GENE
kb O
messages _RARE_
. O

Mice _RARE_
homozygous O
for O
the O
dlg _RARE_
mutation I-GENE
exhibit O
growth I-GENE
retardation O
in O
utero _RARE_
, O
have O
hypoplasia _RARE_
of O
the O
premaxilla _RARE_
and O
mandible _RARE_
, O
have O
a O
cleft _RARE_
secondary O
palate _RARE_
, O
and O
die _RARE_
perinatally _RARE_
. O

In O
contrast O
, O
we O
did O
not O
detect O
a O
significant O
correlation O
between O
plasma I-GENE
TNFalpha _RARE_
and O
radiation O
pneumonitis _RARE_
. O

Its O
transcription I-GENE
in O
vitro O
by O
pol I-GENE
III I-GENE
requires O
the O
same O
factors I-GENE
as O
the O
U6 I-GENE
gene I-GENE
with O
the O
major I-GENE
exception O
that O
the O
modified O
TATA I-GENE
- I-GENE
box I-GENE
of O
this O
construct I-GENE
only O
interacts O
with O
a O
TATA I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( O
TBP I-GENE
) O
mutant I-GENE
( O
TBP I-GENE
- I-GENE
DR2 _RARE_
) O
but O
not O
with O
TBP I-GENE
wild I-GENE
- I-GENE
type I-GENE
( O
TBPwt _RARE_
). O

Expression O
of O
the O
src I-GENE
homology I-GENE
3 I-GENE
( O
SH3 I-GENE
)- I-GENE
encoding O
, O
expressed O
in O
tumorigenic O
astrocytes _RARE_
( O
SETA _RARE_
) O
gene I-GENE
is O
associated I-GENE
with O
astrocyte _RARE_
transformation O
in O
culture O
and O
tumors O
in O
the O
adult O
brain O
. O

In O
such O
conditions O
, O
the O
following O
kinetic O
reactions O
have O
been O
studied O
: O
N2 O
( O
A I-GENE
) O
+ I-GENE
N2 O
( O
A I-GENE
) O
--> O
N2 O
( O
C I-GENE
, O
B I-GENE
, O
V I-GENE
') _RARE_
+ I-GENE
N2 O
( O
X I-GENE
), O
N2 O
( O
A I-GENE
) O
+ I-GENE
N2 O
( O
X I-GENE
, O
V I-GENE
> O
5 I-GENE
) O
--> O
N2 O
( O
X I-GENE
) O
+ I-GENE
N2 O
( O
B I-GENE
, O
V I-GENE
') _RARE_
in O
pure O
N2 O
post O
- I-GENE
discharges _RARE_
and O
N2 O
( O
A I-GENE
) O
+ I-GENE
CH4 _RARE_
--> O
products I-GENE
, O
C I-GENE
+ I-GENE
N I-GENE
+ I-GENE
M2 _RARE_
--> O
CN _RARE_
( O
B I-GENE
, O
V I-GENE
') _RARE_
+ I-GENE
M2 _RARE_
, O
N2 O
( O
X I-GENE
, O
V I-GENE
> O
4 I-GENE
) O
+ I-GENE
CN _RARE_
--> O
N2 O
( O
X I-GENE
) O
+ I-GENE
CN _RARE_
( O
B I-GENE
, O
A I-GENE
, O
V I-GENE
'), _RARE_
in O
N2 O
- I-GENE
1 I-GENE
% O
CH4 _RARE_
post O
- I-GENE
discharges _RARE_
. O

BACKGROUND O
/ I-GENE
AIMS _RARE_
: O
Hepatitis _RARE_
C I-GENE
and O
nonalcoholic _RARE_
fatty I-GENE
liver O
disease O
( O
NAFL _RARE_
) O
are O
the O
two O
most O
common O
forms O
of O
liver O
disease O
in O
the O
United O
States _RARE_
. O

These O
results O
suggested O
a O
critical O
role O
for O
tyrosine I-GENE
residue O
1229 _RARE_
in O
the O
regulation O
of O
L1 I-GENE
endocytosis _RARE_
. O

The O
androgen O
receptor I-GENE
( O
AR I-GENE
) O
amino O
- I-GENE
terminus O
imposes _RARE_
androgen O
- I-GENE
specific I-GENE
regulation O
of O
AR I-GENE
gene I-GENE
expression O
via O
an O
exonic _RARE_
enhancer I-GENE
. O

Can _RARE_
survival O
be O
prolonged O
for O
patients O
with O
hormone I-GENE
- I-GENE
resistant O
prostate O
cancer O
? O

In O
conclusion O
, O
NF I-GENE
- I-GENE
Y I-GENE
and O
Sp1 I-GENE
binding I-GENE
sites I-GENE
play O
a O
decisive _RARE_
role O
in O
the O
basal O
expression O
of O
the O
rat I-GENE
mrp2 _RARE_
gene I-GENE
, O
while O
the O
human I-GENE
MRP2 _RARE_
gene I-GENE
is O
regulated O
differently O
. O

Intact _RARE_
Flag _RARE_
- I-GENE
tagged O
protein I-GENE
products I-GENE
from O
all O
six O
were O
produced O
from O
genomic O
expression O
vectors O
, O
although O
the O
ORF40 _RARE_
/ I-GENE
41 O
transcript I-GENE
encoding O
a O
primase I-GENE
- I-GENE
helicase I-GENE
component O
proved O
to O
be O
spliced O
with O
a O
127 _RARE_
- I-GENE
bp O
intron O
. O

Hypomorphic _RARE_
dSLBP _RARE_
alleles I-GENE
support O
zygotic _RARE_
development O
but O
cause O
female O
sterility _RARE_
. O

In O
hypertensive O
nephrosclerosis _RARE_
, O
therapy O
containing O
an O
ACEI _RARE_
alone O
or O
in O
combination O
significantly O
reduces O
the O
incidence O
of O
renal O
events O
. O

We O
confirmed O
the O
interaction O
between O
TLS _RARE_
and O
p65 I-GENE
by O
the O
pull _RARE_
- I-GENE
down O
assay O
in O
vitro O
and O
by O
a O
coimmunoprecipitation _RARE_
experiment O
followed O
by O
Western O
blot O
of O
the O
cultured O
cell O
in O
vivo O
. O

In O
addition O
, O
we O
did O
not O
detect O
significant O
differences O
in O
CDR3 _RARE_
sequences I-GENE
of O
endogenous I-GENE
Ig I-GENE
lambdaL _RARE_
and O
kappaL _RARE_
chain I-GENE
gene I-GENE
loci I-GENE
cloned O
from O
peripheral O
blood O
lymphocytes O
of O
an O
NBS _RARE_
patient O
and O
of O
healthy O
individuals O
. O

The O
diet O
of O
migrants _RARE_
showed O
both O
positive O
( O
macronutrients _RARE_
) O
and O
negative O
( O
micronutrients _RARE_
) O
differences O
with O
the O
general O
Dutch _RARE_
diet O
. O

Copyright O
2001 _RARE_
Academic O
Press O
. O

Experimental O
study O
of O
ta _RARE_
chengchi _RARE_
tang _RARE_
decoction _RARE_
for O
relieving _RARE_
lung O
injury O
during O
acute O
necrotizing _RARE_
pancreatitis O
] O
The O
objectives _RARE_
of O
the O
study O
were O
to O
investigate O
the O
changes O
of O
leukocyte _RARE_
adhesiveness _RARE_
and O
tumor I-GENE
necrosis I-GENE
factor I-GENE
( O
TNF I-GENE
) O
in O
the O
early I-GENE
stage O
of O
acute O
necrotizing _RARE_
pancreatitis O
( O
ANP I-GENE
), O
to O
go _RARE_
further O
into O
the O
relation O
of O
those O
changes O
to O
lung O
injury O
of O
ANP I-GENE
, O
and O
to O
evaluate O
the O
prohibitive _RARE_
effect O
of O
ta _RARE_
chengchi _RARE_
tang _RARE_
Decoction _RARE_
on O
leukocyte _RARE_
adhesion I-GENE
and O
TNF I-GENE
secretion O
. O

We O
suggest O
that O
ventriculopleural _RARE_
shunting _RARE_
should O
be O
considered O
as O
the O
preferred O
alternative O
to O
peritoneal O
drainage O
in O
children O
with O
intra O
- I-GENE
abdominal O
adhesions O
or O
with O
a O
history O
of O
recent O
peritoneal O
infection O
. O

Positive _RARE_
and O
significant O
correlations O
were O
found O
between O
the O
weeks O
of O
pregnancy O
and O
Se _RARE_
levels O
in O
kidney O
( O
r O
= O
0 O
. O
433 _RARE_
, O
P I-GENE
= O
0 O
. O
023 _RARE_
) O
and O
heart O
( O
r O
= O
0 O
. O
313 _RARE_
, O
P I-GENE
= O
0 O
. O
030 _RARE_
). O

Doxorubicin _RARE_
( O
DOX _RARE_
) O
is O
commonly O
used O
for O
the O
treatment O
of O
hematological _RARE_
and O
solid O
tumors O
. O

There O
was O
no O
significant O
difference O
in O
developmental O
scores O
at O
9 O
or O
18 O
months O
, O
although O
PDF _RARE_
infants O
had O
a O
2 I-GENE
. O
8 I-GENE
(- O
1 I-GENE
. O
3 I-GENE
- I-GENE
6 I-GENE
. O
8 I-GENE
) O
point O
advantage O
in O
Bayley _RARE_
motor O
score O
scales _RARE_
. O

Immunofixation _RARE_
experiments O
of O
C4A _RARE_
and O
C4B _RARE_
demonstrate O
> O
41 O
allotypes _RARE_
in O
the O
two O
classes O
of O
proteins I-GENE
. O

These O
effects O
were O
not O
seen O
with O
SHIP2 _RARE_
possessing _RARE_
a O
mutation I-GENE
in O
the O
SH2 I-GENE
domain I-GENE
( O
R47G _RARE_
). O

Myasthenia _RARE_
gravis _RARE_
is O
an O
autoimmune _RARE_
disease O
resulting O
from O
the O
production O
of O
antibodies I-GENE
against O
the O
ACh _RARE_
receptors I-GENE
of O
the O
neuromuscular O
synapse _RARE_
. O

Human I-GENE
homologue I-GENE
of O
yeast I-GENE
Rad23 _RARE_
protein I-GENE
A I-GENE
interacts O
with O
p300 I-GENE
/ I-GENE
cyclic I-GENE
AMP I-GENE
- I-GENE
responsive I-GENE
element I-GENE
binding I-GENE
( O
CREB I-GENE
)- I-GENE
binding I-GENE
protein I-GENE
to O
down O
- I-GENE
regulate O
transcriptional O
activity O
of O
p53 I-GENE
. O

METHODS O
: O
Sixteen _RARE_
pigs O
were O
assigned O
randomly O
to O
control O
and O
shock I-GENE
groups O
. O

RESULTS O
: O
There O
is O
a O
considerable O
amount O
of O
variation O
between O
the O
results O
of O
TRA1 _RARE_
and O
TRA2 _RARE_
and O
between O
the O
results O
of O
both O
TRA _RARE_
' O
s O
and O
the O
door _RARE_
- I-GENE
to O
- I-GENE
door _RARE_
survey O
. O

Thus O
, O
our O
studies O
define O
Rac I-GENE
/ I-GENE
Cdc42 I-GENE
/ I-GENE
Pak _RARE_
as O
a O
module _RARE_
upstream I-GENE
of O
Raf I-GENE
- I-GENE
1 I-GENE
during O
its O
activation O
by O
microtubule I-GENE
disruption O
. O

Zhu _RARE_
, O
V I-GENE
. O

However O
, O
plasmids O
carrying O
the O
yeast I-GENE
TyrRS _RARE_
gene I-GENE
could O
not O
be O
stably O
maintained O
in O
E I-GENE
. O
coli I-GENE
. O

This O
supports O
previous O
arguments _RARE_
for O
the O
improbability _RARE_
of O
biological O
effects O
at O
UHF _RARE_
frequencies O
unless O
a O
mechanism O
can O
be O
found O
for O
accumulating _RARE_
energy O
over O
time O
and O
space O
and O
focussing _RARE_
it O
. O

The O
students O
who O
had O
abnormal O
urine O
screening O
results O
at O
the O
first O
time O
received O
a O
second O
urine O
analysis O
10 O
to O
15 O
days O
later O
to O
confirm O
the O
abnormal O
urine O
analysis O
. O

Cells _RARE_
containing O
alpha I-GENE
subunits I-GENE
that O
lacked O
a O
distal O
domain I-GENE
( O
term O
- I-GENE
3 I-GENE
) O
or O
had O
the O
alternatively O
spliced O
alpha I-GENE
- I-GENE
2 I-GENE
distal O
domain I-GENE
showed O
markedly O
decreased O
ability O
to O
support O
tyrosine I-GENE
phosphorylation O
of O
Jak I-GENE
- I-GENE
2 I-GENE
and O
its O
substrates O
or O
to O
up O
- I-GENE
regulate O
CD86 _RARE_
. O

Despite O
abundant O
expression O
of O
NtmybAS _RARE_
transcripts I-GENE
in O
mature O
pollen O
, O
gPAL1 _RARE_
transcripts I-GENE
were O
not O
detectable O
in O
pollen O
. O

Finally O
, O
profiling _RARE_
of O
a O
gcn4Delta _RARE_
mutant I-GENE
uncovered _RARE_
an O
alternative O
induction O
pathway O
operating O
at O
many O
Gcn4p _RARE_
target O
genes I-GENE
in O
histidine O
- I-GENE
starved _RARE_
cells O
. O

The O
R2 _RARE_
between O
MFI _RARE_
of O
fresh O
and O
frozen _RARE_
muscle I-GENE
was O
0 O
. O
94 O
and O
0 O
. O
92 O
for O
lamb _RARE_
and O
pork _RARE_
longissimus _RARE_
, O
respectively O
. O

To O
this O
end O
, O
an O
expression O
cassette _RARE_
consisting O
of O
the O
gene I-GENE
for O
a O
green _RARE_
fluorescent O
protein I-GENE
( O
GFP _RARE_
) O
flanked O
at O
its O
3 I-GENE
' O
end O
by O
EAV _RARE_
- I-GENE
specific I-GENE
transcription I-GENE
- I-GENE
regulating O
sequences I-GENE
was O
constructed O
. O

Significantly O
higher O
lung O
function O
parameters O
were O
obtained O
in O
extubated _RARE_
recipients O
of O
LPD _RARE_
preserved _RARE_
grafts O
2 I-GENE
weeks O
after O
TX _RARE_
. O

Lack _RARE_
of O
association O
between O
Kawasaki _RARE_
syndrome O
and O
infection O
with O
Rickettsia _RARE_
conorii _RARE_
, O
Rickettsia _RARE_
typhi _RARE_
, O
Coxiella _RARE_
burnetii _RARE_
or O
Ehrlichia _RARE_
phagocytophila _RARE_
group O
. O

These O
utilisation _RARE_
data O
imply O
annual O
drug O
costs O
in O
the O
range O
of O
$ _RARE_
US O
480 _RARE_
, O
000 O
to O
$ _RARE_
US O
3 I-GENE
, O
600 O
, O
000 O
for O
TNF I-GENE
antagonists O
for O
RA O
per O
1 I-GENE
million O
population O
. O

Alignment _RARE_
of O
different O
cDNAs I-GENE
of O
the O
NR5A2 _RARE_
( O
hB1F _RARE_
) O
gene I-GENE
with O
the O
genomic O
sequence I-GENE
facilitated O
the O
delineation _RARE_
of O
its O
structural O
organization O
, O
which O
spans O
over O
150 O
kb O
and O
consists O
of O
eight O
exons O
interrupted O
by O
seven O
introns O
. O

CONCLUSIONS O
: O
Ketamine _RARE_
- I-GENE
induced O
dissociative _RARE_
anesthesia O
produces O
persistently _RARE_
elevated O
BIS _RARE_
index O
which O
is O
different O
from O
thiamylal _RARE_
and O
those O
reported O
with O
other O
conventional O
anesthetic _RARE_
agents O
. O

In O
the O
remaining O
case O
, O
the O
aneurysm _RARE_
originated _RARE_
from O
the O
proximal I-GENE
end O
of O
the O
associated I-GENE
A1 I-GENE
fenestration _RARE_
. O

This O
domain I-GENE
without O
the O
canonical O
anticodon _RARE_
loop I-GENE
or O
the O
tyrosine I-GENE
anticodon _RARE_
acts O
as O
an O
anchor _RARE_
for O
TyrRS _RARE_
interaction O
leading O
to O
a O
better O
efficiency O
of O
tyrosylation _RARE_
. O

Temperature _RARE_
measurement O
in O
microfluidic _RARE_
systems O
using O
a O
temperature O
- I-GENE
dependent I-GENE
fluorescent O
dye O
. O

The O
first O
exon O
( O
exon O
1A _RARE_
) O
that O
corresponded O
to O
the O
5 I-GENE
'- I-GENE
untranslated O
region I-GENE
of O
the O
GHR _RARE_
1A _RARE_
mRNA I-GENE
was O
15 O
, O
250 O
bp O
upstream I-GENE
from O
exon O
2 I-GENE
in O
the O
GHR _RARE_
gene I-GENE
. O

The O
NAUSICAA _RARE_
system O
gives O
a O
good O
knowledge O
of O
LET _RARE_
spectra O
for O
the O
first O
time O
in O
space O
dosimetry _RARE_
. O

The O
MABP _RARE_
and O
MCBFV _RARE_
signals O
were O
bandpass _RARE_
filtered _RARE_
in O
the O
very O
low O
- I-GENE
frequency O
range O
( O
VLF _RARE_
, O
0 O
. O
015 _RARE_
- I-GENE
0 O
. O
07 O
Hz O
), O
low O
- I-GENE
frequency O
range O
( O
LF _RARE_
, O
0 O
. O
07 O
- I-GENE
0 O
. O
15 O
Hz O
) O
and O
high O
- I-GENE
frequency O
range O
( O
HF _RARE_
, O
0 O
. O
15 O
- I-GENE
0 O
. O
40 I-GENE
Hz O
) O
before O
applying O
CCF _RARE_
for O
the O
purpose O
of O
studying O
the O
effect O
of O
different O
bandwidths _RARE_
on O
the O
resulting O
mean O
CCFs _RARE_
. O

At O
cross O
purposes _RARE_
. O

For O
these O
patients O
the O
introduction O
of O
a O
separate O
category O
" O
extended O
oligoarthritis _RARE_
at O
onset O
" O
should O
be O
considered O
to O
establish O
comparable O
patient O
groups O
. O

The O
susceptibility _RARE_
of O
Aspergillus _RARE_
fumigatus _RARE_
to O
mulundocandin _RARE_
, O
an O
echinocandin _RARE_
- I-GENE
like I-GENE
compound O
, O
and O
other O
antifungal _RARE_
agents O
was O
assessed O
by O
the O
National O
Committee O
for O
Clinical O
Laboratory O
Standards _RARE_
( O
NCCLS _RARE_
) O
M38 _RARE_
- I-GENE
P I-GENE
method O
, O
a O
2 I-GENE
, O
3 I-GENE
- I-GENE
bis _RARE_
( O
2 I-GENE
- I-GENE
methoxy _RARE_
- I-GENE
4 I-GENE
- I-GENE
nitro _RARE_
- I-GENE
5 I-GENE
- I-GENE
sulfophenyl _RARE_
)- I-GENE
5 I-GENE
-[( _RARE_
phenyl _RARE_
- I-GENE
amino O
) O
carbonyl _RARE_
]- _RARE_
2H _RARE_
- I-GENE
tetrazolium _RARE_
hydroxide _RARE_
( O
XTT _RARE_
)- I-GENE
based O
colorimetric _RARE_
assay O
, O
and O
determination O
of O
morphologic O
alterations O
by O
microscopy O
. O

The O
most O
important O
risk O
factors I-GENE
are O
: O
1 I-GENE
) O
genetic O
; O
2 I-GENE
) O
Epstein I-GENE
- I-GENE
Barr I-GENE
virus I-GENE
( O
infectious O
mononucleosis _RARE_
); O
3 I-GENE
) O
congenital O
and O
acquired O
immunodeficiency I-GENE
; O
4 I-GENE
) O
occupational _RARE_
exposure O
( O
the O
wood _RARE_
industry _RARE_
). O

Members O
of O
the O
AP I-GENE
- I-GENE
1 I-GENE
superfamily I-GENE
of O
basic I-GENE
- I-GENE
leucine I-GENE
zipper I-GENE
factors I-GENE
bind O
to O
the O
StRE _RARE_
. O

DNA I-GENE
recognition I-GENE
by O
F I-GENE
factor I-GENE
TraI36 _RARE_
: O
highly O
sequence I-GENE
- I-GENE
specific I-GENE
binding I-GENE
of O
single O
- I-GENE
stranded _RARE_
DNA I-GENE
. O

Overexpression O
of O
RORgamma _RARE_
has O
been O
shown O
to O
inhibit O
T I-GENE
cell O
receptor I-GENE
- I-GENE
mediated O
apoptosis O
in O
T I-GENE
cell O
hybridomas _RARE_
and O
to O
repress O
the O
induction O
of O
Fas I-GENE
- I-GENE
ligand O
and O
interleukin I-GENE
2 I-GENE
. O

Although O
metabolized _RARE_
by O
the O
cytochrome I-GENE
P I-GENE
- I-GENE
450 _RARE_
( O
CYP _RARE_
) O
system O
, O
venlafaxine _RARE_
inhibits O
CYP _RARE_
2D6 _RARE_
and O
3A4 _RARE_
to O
a O
far O
lesser O
extent O
than O
do O
the O
SSRIs _RARE_
. O

SAPK I-GENE
/ I-GENE
JNK I-GENE
activation O
was O
completely O
abolished O
in O
the O
absence O
of O
MKK7 _RARE_
, O
even O
though O
expression O
of O
MKK4 _RARE_
was O
strongly O
upregulated _RARE_
in O
mkk7 _RARE_
(-/-) _RARE_
mast _RARE_
cell O
lines O
, O
and O
phosphorylation O
of O
MKK4 _RARE_
occurred O
normally O
in O
response I-GENE
to O
multiple O
stress I-GENE
stimuli O
. O

However O
these O
search O
engines _RARE_
respond O
with O
such O
cumbersome _RARE_
results O
that O
domain I-GENE
specific I-GENE
experts _RARE_
can O
not O
tolerate _RARE_
. O

The O
titer O
of O
TSH I-GENE
binding I-GENE
inhibitor I-GENE
immunoglobulin I-GENE
( O
TBII _RARE_
), O
which O
had O
been O
8 I-GENE
. O
6 I-GENE
% O
at O
initial O
presentation O
, O
rose O
to O
14 O
. O
9 O
% O
in O
2 I-GENE
weeks O
. O

The O
extraordinary _RARE_
stability O
of O
peptide I-GENE
-- O
gp96 _RARE_
complexes I-GENE
and O
the O
plasticity _RARE_
of O
the O
peptide I-GENE
- I-GENE
binding I-GENE
pocket O
support O
the O
proposed O
relay _RARE_
of O
diverse O
peptides I-GENE
to O
MHC I-GENE
and O
/ I-GENE
or O
other O
molecules I-GENE
via O
molecular O
recognition I-GENE
. O

Elevated _RARE_
expression O
of O
full I-GENE
- I-GENE
length I-GENE
UhpB _RARE_
or O
of O
a O
soluble _RARE_
hybrid O
protein I-GENE
, O
GST I-GENE
- I-GENE
Bc _RARE_
, O
which O
is O
glutathione I-GENE
S I-GENE
- I-GENE
transferase I-GENE
( O
GST I-GENE
) O
fused O
to O
the O
cytoplasmic I-GENE
C I-GENE
- I-GENE
terminal I-GENE
portion O
of O
UhpB _RARE_
, O
results O
in O
complete O
blockage _RARE_
of O
uhpT _RARE_
expression O
in O
a O
uhp _RARE_
(+) _RARE_
strain O
. O

Physical _RARE_
principles _RARE_
in O
therapeutic O
apheresis _RARE_
. O

Evidence O
from O
a O
Northern O
hybridization O
indicated O
that O
jadM _RARE_
expression O
is O
correlated O
with O
jadomycin _RARE_
B I-GENE
synthesis O
. O

Multiple O
copies O
of O
rsmB _RARE_
+ I-GENE
DNA I-GENE
, O
on O
the O
other O
hand O
, O
stimulate O
exoenzyme _RARE_
production O
by O
relieving _RARE_
the O
negative O
effects O
of O
a O
chromosomal I-GENE
copy O
of O
hexA _RARE_
+. _RARE_

Systematic _RARE_
review O
of O
diagnostic O
tests O
for O
vaginal O
trichomoniasis _RARE_
. O

Anecdotal _RARE_
observations O
scattered _RARE_
throughout O
the O
literature O
have O
often O
provided O
clues _RARE_
to O
underlying O
variations O
in O
humans O
' O
ability O
to O
handle _RARE_
dietary O
chemicals _RARE_
. O

Here O
we O
show O
that O
phosphorylation O
- I-GENE
induced O
loss O
of O
the O
protein I-GENE
kinase I-GENE
activity O
of O
DNA I-GENE
- I-GENE
PK I-GENE
is O
restored O
by O
the O
addition O
of O
the O
purified O
catalytic I-GENE
subunit I-GENE
of O
either O
protein I-GENE
phosphatase I-GENE
1 I-GENE
or O
protein I-GENE
phosphatase I-GENE
2A I-GENE
( O
PP2A I-GENE
) O
and O
that O
this O
reactivation _RARE_
is O
blocked O
by O
the O
potent O
protein I-GENE
phosphatase I-GENE
inhibitor I-GENE
, O
microcystin _RARE_
. O

Herein _RARE_
PPARgamma I-GENE
, O
liganded _RARE_
by O
either O
natural O
( O
15d _RARE_
- I-GENE
PGJ _RARE_
( O
2 I-GENE
) O
and O
PGD _RARE_
( O
2 I-GENE
)) O
or O
synthetic O
ligands O
( O
BRL49653 _RARE_
and O
troglitazone _RARE_
), O
selectively O
inhibited O
expression O
of O
the O
cyclin I-GENE
D1 I-GENE
gene I-GENE
. O

An O
integrated O
RTC _RARE_
algorithm O
for O
the O
urban _RARE_
wastewater _RARE_
system O
is O
formulated _RARE_
, O
the O
parameters O
of O
which O
are O
optimized _RARE_
using O
various O
global O
optimization _RARE_
routines _RARE_
. O

Recently O
, O
we O
discovered O
that O
alanine I-GENE
substitutions O
of O
the O
active O
center _RARE_
cleft _RARE_
residues O
significantly O
impair _RARE_
the O
depurinating _RARE_
and O
ribosome _RARE_
inhibitory _RARE_
activity O
of O
PAP _RARE_
. O

This O
partial O
transection _RARE_
could O
permit O
vasopressin I-GENE
to O
be O
secreted O
in O
response I-GENE
to O
a O
larger O
rise O
in O
plasma I-GENE
sodium O
concentration O
. O

Reciprocally _RARE_
, O
HMGI _RARE_
- I-GENE
C I-GENE
expression O
also O
coordinately _RARE_
enhances O
PIAS3 _RARE_
- I-GENE
mediated O
repression O
of O
STAT3 I-GENE
- I-GENE
dependent I-GENE
transactivation O
. O

The O
genomic O
structure O
of O
the O
human I-GENE
SPEC1 _RARE_
gene I-GENE
reveals O
complex I-GENE
splicing O
and O
close O
promoter I-GENE
proximity _RARE_
to O
the O
AF1q _RARE_
translocation O
gene I-GENE
. O

Here O
, O
the O
PEX5 _RARE_
- I-GENE
TPR O
domains I-GENE
from O
human I-GENE
, O
tobacco I-GENE
, O
and O
nematode O
were O
inserted O
into O
a O
TPR O
- I-GENE
less O
yeast I-GENE
Pex5p _RARE_
construct I-GENE
to O
generate O
Pex5p _RARE_
chimaeras _RARE_
. O

This O
study O
demonstrates O
that O
inducible I-GENE
expression O
in O
response I-GENE
to O
either O
PMA O
or O
TPO _RARE_
is O
mediated O
through O
the O
Ets I-GENE
site I-GENE
in O
the O
proximal I-GENE
promoter I-GENE
of O
GPIX _RARE_
and O
is O
dependent I-GENE
upon O
the O
upstream I-GENE
activation O
of O
MAPK I-GENE
/ I-GENE
extracellular I-GENE
signal I-GENE
- I-GENE
regulated O
kinase I-GENE
. O

Molecular O
identification O
of O
smg _RARE_
- I-GENE
4 I-GENE
, O
required O
for O
mRNA I-GENE
surveillance _RARE_
in O
C I-GENE
. O
elegans I-GENE
. O

Cytosolic _RARE_
acetyl I-GENE
- I-GENE
CoA I-GENE
synthetase I-GENE
( O
AceCS1 _RARE_
) O
activates O
acetate O
to O
supply O
the O
cells O
with O
acetyl I-GENE
- I-GENE
CoA I-GENE
for O
lipid O
synthesis O
. O

There O
was O
an O
increase O
in O
protein I-GENE
binding I-GENE
onto O
this O
element I-GENE
only O
after O
peptide I-GENE
treatment O
. O

While O
these O
results O
are O
consistent O
with O
previously O
reported O
effects O
of O
the O
C I-GENE
- I-GENE
terminal I-GENE
domain I-GENE
on O
nucleotide I-GENE
binding I-GENE
, O
they O
also O
demonstrate O
that O
interactions O
with O
the O
N I-GENE
- I-GENE
terminal I-GENE
domains I-GENE
are O
necessary O
to O
inhibit O
proton _RARE_
transport O
. O

These O
findings O
suggest O
that O
an O
intracellular O
WT _RARE_
- I-GENE
1 I-GENE
/ I-GENE
HSAL2 _RARE_
pathway O
may O
play O
a O
role O
in O
development O
and O
hematopoiesis _RARE_
. O

The O
radial _RARE_
forearm _RARE_
flap O
is O
used O
most O
commonly O
, O
however O
the O
lateral O
arm O
flap O
may O
be O
the O
flap O
of O
choice O
in O
certain O
situations O
. O

The O
procedure O
is O
less O
aggressive O
and O
painful _RARE_
than O
sternotomy _RARE_
. O

In O
addition O
, O
we O
have O
isolated O
a O
genomic O
fragment I-GENE
containing O
the O
most O
distal O
5 I-GENE
' O
sequences I-GENE
of O
the O
major I-GENE
GGT _RARE_
mRNA I-GENE
in O
HepG2 O
cells O
. O

Further O
, O
the O
osteo _RARE_
- I-GENE
retentive _RARE_
ability O
of O
the O
hydroxyapatite _RARE_
in O
the O
sockets _RARE_
was O
seen O
to O
be O
close O
to O
significance O
( O
after O
six O
months O
width _RARE_
differences O
, O
in O
the O
canine O
region I-GENE
: O
P I-GENE
= O
0 O
. O
059 _RARE_
, O
LHS _RARE_
, O
and O
P I-GENE
= O
0 O
. O
065 _RARE_
, O
RHS _RARE_
). O

These O
findings O
suggest O
a O
novel O
ankyrin _RARE_
- I-GENE
independent O
role O
for O
LAD O
- I-GENE
1 I-GENE
related I-GENE
to O
FGFR I-GENE
signaling O
. O

Managing _RARE_
vertigo _RARE_
and O
vertigo _RARE_
syndromes O
in O
the O
elderly O

A I-GENE
single O
base O
change O
( O
A8G _RARE_
) O
in O
either O
sequence I-GENE
reduces O
hnRNP I-GENE
A2 I-GENE
binding I-GENE
and O
, O
in O
the O
case O
of O
A2RE _RARE_
- I-GENE
2 I-GENE
, O
inhibits O
RNA I-GENE
transport O
. O

A I-GENE
method O
of O
three O
- I-GENE
station _RARE_
three O
- I-GENE
dimensional O
magnetic O
resonance O
( O
MR O
) O
angiography O
of O
the O
lower O
extremities _RARE_
with O
segmented _RARE_
volume O
acquisition O
is O
presented O
. O

Treatment O
of O
N18TG _RARE_
- I-GENE
2 I-GENE
cells O
with O
a O
demethylating _RARE_
agent O
, O
5 I-GENE
- I-GENE
aza _RARE_
- I-GENE
deoxycytidine _RARE_
, O
resulted O
in O
an O
expression O
of O
mlt _RARE_
1 I-GENE
, O
indicating O
that O
the O
repression O
of O
mlt _RARE_
1 I-GENE
is O
attributable _RARE_
to O
methylation O
Thus O
, O
mlt _RARE_
1 I-GENE
is O
a O
novel O
target O
gene I-GENE
that O
is O
silenced _RARE_
by O
methylation O
during O
liver O
tumorigenesis O
initiated O
by O
SV40 I-GENE
T I-GENE
antigen I-GENE
. O

We O
found O
in O
the O
control O
subjects O
rCBF O
increases O
in O
regions O
associated I-GENE
with O
the O
meso _RARE_
- I-GENE
striatal _RARE_
and O
meso _RARE_
- I-GENE
corticolimbic _RARE_
circuits _RARE_
in O
response I-GENE
to O
both O
monetary _RARE_
reward _RARE_
and O
nonmonetary _RARE_
reinforcement _RARE_
. O

Reverse _RARE_
transcriptase I-GENE
- I-GENE
polymerase I-GENE
chain I-GENE
reaction O
assays O
showed O
that O
PKRDeltaE7 _RARE_
is O
expressed O
in O
a O
broad O
range O
of O
human I-GENE
tissues O
at O
variable O
levels O
. O

For O
this O
purpose O
, O
the O
immediate I-GENE
and O
the O
final O
( O
after O
swelling O
) O
fixation O
strengths O
of O
two O
variations O
of O
the O
swellable _RARE_
bone O
anchor _RARE_
designs _RARE_
( O
a O
smooth _RARE_
anchor _RARE_
and O
a O
screw _RARE_
anchor _RARE_
) O
were O
measured O
in O
two O
different O
foams _RARE_
( O
used O
to O
simulate _RARE_
bone O
) O
with O
different O
densities _RARE_
. O

CYP2C19 _RARE_
genotype _RARE_
was O
determined O
by O
the O
polymerase I-GENE
chain I-GENE
reaction O
- I-GENE
restriction O
fragment I-GENE
length I-GENE
polymorphism O
method O
. O

It O
is O
useful O
as O
an O
adjunct _RARE_
to O
mammography _RARE_
in O
those O
patients O
with O
radiographically _RARE_
dense _RARE_
breasts _RARE_
for O
the O
characterization O
of O
palpable _RARE_
masses O
. O

Activation O
of O
transcription I-GENE
through O
the O
AP I-GENE
- I-GENE
1 I-GENE
site I-GENE
in O
Jurkat O
cells O
by O
JunD _RARE_
and O
/ I-GENE
or O
Fra _RARE_
- I-GENE
2 I-GENE
was O
weak O
. O
c I-GENE
- I-GENE
Jun I-GENE
, O
JunB _RARE_
, O
and O
c I-GENE
- I-GENE
Fos I-GENE
activation O
was O
greater O
, O
although O
the O
level O
was O
still O
less O
than O
that O
with O
Tax I-GENE
. O

Thus O
, O
the O
screen O
for O
toxic O
p53 I-GENE
mutants I-GENE
in O
yeast I-GENE
can O
identify O
novel O
p53 I-GENE
variants I-GENE
that O
may O
be O
useful O
in O
dissecting _RARE_
p53 I-GENE
regulated O
cellular O
responses O
and O
in O
developing O
p53 I-GENE
- I-GENE
based O
cancer O
therapies _RARE_
. O

Local _RARE_
control O
rates O
were O
91 O
% O
for O
metastatic O
lung O
cancer O
, O
89 _RARE_
% O
for O
primary O
lung O
cancer O
and O
85 O
% O
for O
T1 O
, O
2N0M0 _RARE_
cases O
. O

The O
results O
show O
that O
cognitive O
stimulation O
enhanced O
performance O
on O
the O
Boston _RARE_
Naming _RARE_
Test O
and O
a O
Word _RARE_
List _RARE_
Recognition _RARE_
Task _RARE_
; O
physical O
intervention O
, O
however O
, O
did O
not O
reach O
statistical O
significance O
. O

Gimpl _RARE_
, O
F I-GENE
. O

The O
actA _RARE_
gene I-GENE
is O
present O
as O
a O
single O
copy O
in O
the O
genome O
of O
A I-GENE
. O
chrysogenum _RARE_
; O
and O
its O
expression O
level O
, O
opposite O
to O
pcbC _RARE_
and O
cefEF _RARE_
cephalosporin _RARE_
biosynthetic O
genes I-GENE
, O
was O
steady O
during O
cephalosporin _RARE_
fermentation _RARE_
, O
showing O
a O
single O
1 I-GENE
. O
4 I-GENE
- I-GENE
kb O
transcript I-GENE
. O

Maternal _RARE_
p O
, O
p O
' O
DDE _RARE_
and O
beta I-GENE
- I-GENE
HCH _RARE_
levels O
were O
also O
associated I-GENE
with O
newborn O
levels O
, O
but O
levels O
of O
PCBs _RARE_
were O
not O
. O

The O
patients O
and O
their O
families O
were O
closely O
questioned _RARE_
, O
and O
full I-GENE
clinical O
examination O
included O
a O
test O
for O
orthostasia _RARE_
. O

The O
expression O
of O
alpha I-GENE
- I-GENE
amylase I-GENE
can O
be O
transactivated O
by O
the O
transcription I-GENE
factor I-GENE
GAMyb _RARE_
, O
which O
is O
itself O
induced O
by O
GA _RARE_
. O

Cardiac _RARE_
output O
at O
anaerobic O
threshold O
( O
COAT _RARE_
) O
< O
or O
= O
7 O
. O
3 I-GENE
L I-GENE
/ I-GENE
min O
was O
the O
best O
cutoff O
value O
for O
identifying O
multivessel _RARE_
coronary O
artery O
disease O
( O
relative O
risk O
, O
3 I-GENE
. O
1 I-GENE
). O

Tolerance _RARE_
to O
ADAL _RARE_
- I-GENE
2 I-GENE
was O
similar O
to O
that O
of O
Vicryl _RARE_
suture _RARE_
and O
tolerance O
to O
ADAL _RARE_
- I-GENE
2 I-GENE
was O
superior O
to O
that O
to O
Tisuacryl _RARE_
. O

In O
the O
base O
- I-GENE
case O
analysis O
, O
total O
direct O
costs O
per O
patient O
were O
$ _RARE_
728 _RARE_
for O
zoledronic _RARE_
acid I-GENE
and O
$ _RARE_
776 _RARE_
for O
pamidronate _RARE_
. O

METHODS O
: O
We O
retrospectively _RARE_
selected O
13 O
TFCD _RARE_
patients O
who O
underwent O
surgery O
for O
intractable _RARE_
epilepsy O
with O
the O
aim O
of O
removing O
the O
magnetic O
resonance O
( O
MR O
)- I-GENE
detectable O
lesion O
and O
/ I-GENE
or O
the O
epileptogenic _RARE_
zone O
defined O
by O
stereoelectroencephalographic _RARE_
recordings O
. O

To O
gain O
an O
understanding O
of O
the O
mGSTM2 _RARE_
regulation O
, O
we O
have O
also O
cloned O
and O
analyzed O
its O
promoter I-GENE
region I-GENE
. O

Cyclins _RARE_
are O
one O
of O
the O
pivotal O
determinants _RARE_
regulating O
cell O
cycle O
progression O
. O

Architecture _RARE_
and O
anatomy _RARE_
of O
the O
genomic O
locus I-GENE
encoding O
the O
human I-GENE
leukemia I-GENE
- I-GENE
associated I-GENE
transcription I-GENE
factor I-GENE
RUNX1 _RARE_
/ I-GENE
AML1 _RARE_
. O

Three O
of O
the O
proteins I-GENE
involved O
in O
checkpoint _RARE_
signaling O
, O
Rad1 _RARE_
, O
Hus1 _RARE_
, O
and O
Rad9 _RARE_
, O
have O
been O
shown O
to O
interact O
by O
immunoprecipitation O
and O
yeast I-GENE
two O
- I-GENE
hybrid O
studies O
. O

Together O
these O
data O
imply O
that O
the O
HFV _RARE_
R I-GENE
region I-GENE
acts O
in O
the O
nucleus O
to O
modify O
the O
cytoplasmic I-GENE
fate O
of O
target O
HFV _RARE_
mRNA I-GENE
. O

However O
, O
patients O
with O
isolated O
office _RARE_
hypertension O
had O
fewer O
previous O
cardiovascular O
complications O
. O

Through _RARE_
deletion I-GENE
mutagenesis O
, O
we O
identify O
amino O
acids O
2003 _RARE_
to O
2212 _RARE_
of O
CBP I-GENE
, O
which O
we O
call _RARE_
carboxy _RARE_
- I-GENE
terminal I-GENE
region I-GENE
2 I-GENE
( O
CR2 _RARE_
), O
as O
the O
minimal I-GENE
region I-GENE
for O
Tax I-GENE
interaction O
. O

Fetal _RARE_
lung O
volume O
: O
estimation O
at O
MR O
imaging O
- I-GENE
initial O
results O
. O

Plane _RARE_
wave O
geometry _RARE_
is O
impractical _RARE_
for O
clinical O
use O
but O
the O
results O
of O
this O
work O
encouraged _RARE_
us O
to O
further O
develop O
the O
P3 O
approximation _RARE_
for O
a O
spherical _RARE_
geometry _RARE_
, O
described O
in O
this O
paper O
. O

For O
the O
sample O
of O
systematic O
reviews _RARE_
drawn _RARE_
from O
ACP _RARE_
Journal _RARE_
Club _RARE_
( O
n O
= O
103 _RARE_
), O
the O
PubMed _RARE_
strategy O
achieved O
a O
sensitivity O
of O
97 O
% O
( O
CI O
, O
91 O
% O
to O
99 O
%). O

In O
addition O
to O
that O
, O
she _RARE_
received O
hepatic _RARE_
intra O
- I-GENE
arterial O
infusion O
of O
levoforinate _RARE_
( O
l O
- I-GENE
LV O
) O
250 O
mg O
and O
5 I-GENE
- I-GENE
fluorouracil O
( O
5 I-GENE
- I-GENE
FU O
) O
500 O
mg O
for O
combined O
multiple O
hepatic _RARE_
metastases O
starting O
on O
postoperative O
day O
14 O
, O
and O
these O
medications _RARE_
were O
administered O
over O
48 O
hours O
once O
weekly O
by O
infuser _RARE_
pump O
. O

Because O
of O
differences O
in O
patient O
characteristics O
, O
control O
measurements O
were O
obtained O
from O
normal O
muscle I-GENE
in O
all O
patients O
. O

Two O
families O
with O
concordant _RARE_
inheritance _RARE_
of O
DNAH9 _RARE_
alleles I-GENE
in O
affected O
individuals O
were O
observed O
. O

NIRS _RARE_
was O
used O
for O
the O
quantitative O
measurement O
of O
muscle I-GENE
O I-GENE
( O
2 I-GENE
) O
consumption O
( O
mV _RARE_
. O
O I-GENE
( O
2 I-GENE
)) O
and O
forearm _RARE_
blood O
flow O
( O
FBF _RARE_
) O
in O
78 O
healthy O
subjects O
. O

Many O
factors I-GENE
do O
influence O
the O
educational _RARE_
outcome O
in O
students O
and O
large O
statistical O
power O
( O
such O
as O
meta _RARE_
analysis O
) O
should O
be O
helpful O
to O
eliminate _RARE_
many O
sources O
of O
error O
. O

B I-GENE
- I-GENE
myb I-GENE
is O
essential O
for O
G1 I-GENE
/ I-GENE
S I-GENE
transition O
and O
has O
been O
shown O
to O
be O
phosphorylated O
by O
the O
cyclin I-GENE
A2 I-GENE
/ I-GENE
cdk2 I-GENE
complex I-GENE
. O

Like O
the O
consensus I-GENE
mammalian I-GENE
LHbeta _RARE_
gene I-GENE
, O
the O
5 I-GENE
'- I-GENE
flanking O
region I-GENE
of O
the O
gpLH _RARE_
/ I-GENE
CGbeta _RARE_
gene I-GENE
contains O
a O
single O
TATA I-GENE
sequence I-GENE
37 O
bp O
upstream I-GENE
of O
the O
translation I-GENE
start O
codon O
. O

HTLV _RARE_
- I-GENE
1 I-GENE
decreases O
Th2 _RARE_
type I-GENE
of O
immune I-GENE
response I-GENE
in O
patients O
with O
strongyloidiasis _RARE_
. O

Indeed O
, O
mutation I-GENE
of O
two O
of O
these O
motifs I-GENE
, O
known O
to O
be O
important O
to O
regulation O
of O
sid1 _RARE_
, O
altered O
the O
differential O
regulation O
of O
sid2 _RARE_
by O
iron O
. O

Nutritional _RARE_
status O
in O
adults O
on O
an O
alternative O
or O
traditional _RARE_
diet O
] O
BACKGROUND O
: O
Plant _RARE_
food O
lacks O
vitamin I-GENE
B12 _RARE_
, O
vitamin I-GENE
D I-GENE
and O
higher O
n O
- I-GENE
3 I-GENE
polyunsaturated _RARE_
fatty I-GENE
acids O
. O

On O
the O
other O
hand O
, O
forced _RARE_
overexpression O
of O
the O
wild I-GENE
type I-GENE
, O
but O
not O
the O
kinase I-GENE
- I-GENE
inactivated O
mutant I-GENE
of O
nm23H1 _RARE_
, O
converted O
the O
GDP I-GENE
- I-GENE
bound O
forms O
of O
Rac1 I-GENE
, O
Cdc42 I-GENE
, O
and O
RhoA I-GENE
to O
their O
GTP I-GENE
- I-GENE
bound O
forms O
in O
vitro O
by O
its O
nucleoside _RARE_
diphosphate _RARE_
kinase I-GENE
activity O
, O
but O
nm23H1 _RARE_
alone O
apparently O
did O
not O
produce O
the O
GTP I-GENE
- I-GENE
bound O
form O
of O
these O
GTPases I-GENE
in O
vivo O
. O

Novel _RARE_
intronic _RARE_
promoter I-GENE
in O
the O
rat I-GENE
ER I-GENE
alpha I-GENE
gene I-GENE
responsible O
for O
the O
transient O
transcription I-GENE
of O
a O
variant I-GENE
receptor I-GENE
. O

RESULTS O
: O
Coronary O
mortality O
during O
the O
median O
follow O
- I-GENE
up O
time O
of O
17 O
months O
was O
6 I-GENE
- I-GENE
fold O
higher O
in O
the O
highest O
tertile _RARE_
for O
CRP I-GENE
and O
IL I-GENE
- I-GENE
6 I-GENE
and O
3 I-GENE
. O
5 I-GENE
- I-GENE
fold O
higher O
in O
the O
highest O
tertile _RARE_
for O
fibrinogen I-GENE
and O
TNF I-GENE
- I-GENE
alpha I-GENE
than O
in O
the O
respective O
combined O
lower O
tertiles _RARE_
. O

HIV I-GENE
- I-GENE
1 I-GENE
and O
hepatitis I-GENE
B I-GENE
virus I-GENE
infections O
in O
adolescents _RARE_
lodged _RARE_
in O
security _RARE_
institutes _RARE_
of O
Buenos _RARE_
Aires _RARE_
. O

However O
, O
the O
promoter I-GENE
region I-GENE
contains O
several O
potential O
cis O
- I-GENE
regulatory I-GENE
elements I-GENE
such O
as O
Sp1 I-GENE
, O
early I-GENE
growth I-GENE
response I-GENE
- I-GENE
1 I-GENE
, O
activator I-GENE
protein I-GENE
- I-GENE
2 I-GENE
, O
MyoD I-GENE
, O
p300 I-GENE
, O
nuclear I-GENE
factor I-GENE
- I-GENE
kappaB I-GENE
, O
myeloid O
zinc I-GENE
finger I-GENE
protein I-GENE
- I-GENE
1 I-GENE
, O
caudal _RARE_
- I-GENE
related I-GENE
homeobox I-GENE
( O
Cdx _RARE_
) O
gene I-GENE
A I-GENE
, O
and O
Cdx _RARE_
protein I-GENE
- I-GENE
2 I-GENE
binding I-GENE
sites I-GENE
. O

RPM _RARE_
/ I-GENE
RGL3 _RARE_
resembled _RARE_
AF _RARE_
- I-GENE
6 I-GENE
and O
Nore1 _RARE_
in O
interacting _RARE_
strongly O
with O
constitutively O
active O
M I-GENE
- I-GENE
Ras I-GENE
and O
p21 I-GENE
Ras I-GENE
. O

METHODS O
: O
93 O
female O
and O
43 _RARE_
male O
patients O
undergoing O
thyroid I-GENE
surgery O
were O
stratified _RARE_
according O
to O
gender O
and O
then O
randomised O
to O
receive O
double I-GENE
- I-GENE
blind O
one O
of O
four O
antiemetic _RARE_
regimes _RARE_
: O
50 O
mg O
dolasetron _RARE_
given O
orally O
45 O
minutes O
prior O
to O
induction O
of O
anaesthesia O
( O
group O
I I-GENE
), O
12 O
. O
5 I-GENE
mg O
dolasetron _RARE_
given O
intravenously O
during O
induction O
of O
anaesthesia O
( O
group O
II I-GENE
), O
1 I-GENE
. O
25 O
mg O
DHB _RARE_
given O
intravenously O
during O
induction O
of O
anaesthesia O
( O
group O
III I-GENE
) O
or O
placebo O
( O
group O
IV I-GENE
). O

Transcriptional O
regulation O
of O
the O
estrogen I-GENE
- I-GENE
inducible I-GENE
pS2 _RARE_
breast O
cancer O
marker O
gene I-GENE
by O
the O
ERR _RARE_
family I-GENE
of O
orphan I-GENE
nuclear I-GENE
receptors I-GENE
. O

